

Supplemental Material

Table of contents

| | |
|---|----|
| S1. European subregion of residence subdivision | 2 |
| S2. European subregion and world region of origin subdivision | 3 |
| S3. Sample description reporting all vaccine acceptance categories | 5 |
| S4. Description of the sample by region | 9 |
| Central Europe | 9 |
| South-East Europe | 11 |
| Baltics | 13 |
| Eastern Europe | 15 |
| Mediterranean Europe | 17 |
| Northern Europe | 19 |
| Western Europe | 22 |
| S5. Model specification | 25 |
| S6. Baseline MPX vaccine acceptance probabilities. | 28 |
| S7. Factor association with MPX vaccine acceptance. | 30 |
| S8. Factor association with MPX vaccine acceptance by European subregion and country. | 34 |
| S9. Association plot | 51 |
| General plot | 51 |
| Migrant birth region plot | 52 |
| S10. Session Info | 53 |
| References | 54 |

This supplementary material is hosted by Eurosurveillance as supporting information alongside the article “High monkeypox vaccine acceptance among male users of smartphone-based online gay-dating apps in Europe, 30 July to 12 August 2022” on behalf of the authors who remain responsible for the accuracy and appropriateness of the content. The same standards for ethics, copyright, attributions and permissions as for the article apply. Supplements are not edited by Eurosurveillance and the journal is not responsible for the maintenance of any links or email addresses provided therein.

S1. European subregion of residence subdivision

Respondent's countries of residence were grouped into European subregions to account for cultural similarities and compensate for noisy estimates for countries with a low number of responses to the survey.

Central Europe:

Czechia, Hungary, Poland, Republic of Moldova, Romania, Slovakia, Ukraine.

South-East Europe:

Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Montenegro, North Macedonia, Serbia, Slovenia, Türkiye.

Baltics:

Estonia, Latvia, Lithuania.

Eastern Europe:

Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Uzbekistan.

Mediterranean Europe:

Greece, Israel, Italy, Malta, Portugal, Spain.

Northern Europe:

Denmark, Finland, Iceland, Norway, Sweden.

Western Europe:

Andorra, Austria, Belgium, France, Germany, Ireland, Liechtenstein, Luxembourg, Monaco, Netherlands, Switzerland, United Kingdom.

S2. European subregion and world region of origin subdivision

A similar approach was used for the countries of origin/birth.

Baltics:

Estonia, Latvia, Lithuania.

Caribbean:

Antigua and Barbuda, Aruba, Bahamas, Barbados, Cuba, Dominica, Dominican Republic, Haiti, Jamaica, Trinidad and Tobago.

Central America:

Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama.

Central Europe:

Czechia, Hungary, Poland, Republic of Moldova, Romania, Slovakia, Ukraine.

Eastern Europe:

Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, Turkmenistan, Uzbekistan.

Eastern Mediterranean:

Afghanistan, Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Pakistan, Saudi Arabia, Syrian Arab Republic, Tunisia, United Arab Emirates, Yemen.

Mediterranean Europe:

Greece, Israel, Italy, Malta, Portugal, San Marino, Spain.

Northern America:

Canada, United States of America.

Northern Europe:

Denmark, Finland, Iceland, Norway, Sweden.

South America:

Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Suriname, Uruguay, Venezuela.

South-East Asia:

Bangladesh, India, Indonesia, Maldives, North Korea, Sri Lanka, Thailand, Timor-Leste.

South-East Europe:

Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Montenegro, North Macedonia, Serbia, Slovenia, Türkiye.

Sub-Saharan Africa:

Angola, Benin, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Comoros, Congo, Côte D'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Ghana, Guinea, Guinea Bissau, Kenya, Liberia, Madagascar, Mali, Mauritius, Mozambique, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Somalia, South Africa, South Sudan, Togo, Uganda, Zambia, Zimbabwe.

Western Europe:

Andorra, Austria, Belgium, France, Germany, Ireland, Liechtenstein, Luxembourg, Monaco, Netherlands, Switzerland, United Kingdom.

Western Pacific:

Australia, Brunei Darussalam, China, Fiji, Japan, Laos, Malaysia, Mongolia, New Zealand, Papua New Guinea, Philippines, Singapore, South Korea, Viet Nam.

S3. Sample description reporting all vaccine acceptance categories

We describe the sample reporting all items the vaccine acceptance question (i.e., the five-point Likert-type rating scale plus unwillingness to answer and missing answers). In the manuscript text we collapsed the responses in four group for easier readability. See the manuscript for the description of the table.

Description of the sample using all vaccine acceptance question items.

| Question | Sample Description | MPX Vaccine acceptance | | | | | | |
|---|--------------------|------------------------|----------------|----------------|----------------|------------------------|----------------------|----------------|
| | | I will get vaccinated | Probably yes | Not sure | Probably not | I won't get vaccinated | Prefer not to answer | Missing |
| Total, N (%) | 32902 (100) | 20266 (61.6) | 6714 (20.4) | 2890 (8.8) | 1236 (3.8) | 1450 (4.4) | 145 (0.4) | 201 (0.6) |
| Preferred place to get vaccinated, N (%) | | | | | | | | |
| In an STI clinic | 3399 (11.1) | 2344 (69) | 668 (19.7) | 281 (8.3) | 96 (2.8) | 0 (0) | 10 (0.3) | 0 (0) |
| With my general practitioner | 5140 (16.8) | 2969 (57.8) | 1309 (25.5) | 609 (11.8) | 233 (4.5) | 0 (0) | 20 (0.4) | 0 (0) |
| In a community-based centre | 1234 (4) | 693 (56.2) | 345 (28) | 153 (12.4) | 40 (3.2) | 0 (0) | 3 (0.2) | 0 (0) |
| In a vaccination program centre | 5493 (17.9) | 3123 (56.9) | 1522 (27.7) | 615 (11.2) | 215 (3.9) | 0 (0) | 16 (0.3) | 2 (0) |
| It doesn't matter | 14473 (47.2) | 10487 (72.5) | 2599 (18) | 950 (6.6) | 416 (2.9) | 0 (0) | 21 (0.1) | 0 (0) |
| I don't know | 794 (2.6) | 137 (17.3) | 160 (20.2) | 238 (30) | 188 (23.7) | 0 (0) | 71 (8.9) | 0 (0) |
| Missing | 134 (0.4) | 44 (32.8) | 15 (11.2) | 14 (10.4) | 17 (12.7) | 0 (0) | 4 (3) | 40 (29.9) |
| Age, Median (IQR) | 38.0 (30 - 47) | 39.0 (31 - 48) | 37.0 (28 - 47) | 35.0 (27 - 45) | 36.0 (28 - 45) | 36.5 (28 - 45) | 35.0 (28 - 44) | 40.0 (31 - 51) |
| Age category, N (%) | | | | | | | | |
| 18-29 | 7724 (23.5) | 4083 (52.9) | 1884 (24.4) | 915 (11.8) | 366 (4.7) | 401 (5.2) | 42 (0.5) | 33 (0.4) |
| 30-39 | 9802 (29.8) | 6100 (62.2) | 1903 (19.4) | 859 (8.8) | 389 (4) | 438 (4.5) | 46 (0.5) | 67 (0.7) |
| 40-49 | 8549 (26) | 5618 (65.7) | 1602 (18.7) | 626 (7.3) | 258 (3) | 375 (4.4) | 32 (0.4) | 38 (0.4) |
| 50-84 | 6827 (20.7) | 4465 (65.4) | 1325 (19.4) | 490 (7.2) | 223 (3.3) | 236 (3.5) | 25 (0.4) | 63 (0.9) |
| Region of residence, N (%) | | | | | | | | |
| Baltics | 131 (0.4) | 74 (56.5) | 32 (24.4) | 15 (11.5) | 6 (4.6) | 4 (3.1) | 0 (0) | 0 (0) |
| Central Europe | 2628 (8) | 1048 (39.9) | 712 (27.1) | 376 (14.3) | 216 (8.2) | 256 (9.7) | 16 (0.6) | 4 (0.2) |
| Eastern Europe | 1602 (4.9) | 529 (33) | 531 (33.1) | 274 (17.1) | 87 (5.4) | 162 (10.1) | 17 (1.1) | 2 (0.1) |
| Mediterranean Europe | 11424 (34.7) | 7723 (67.6) | 2103 (18.4) | 856 (7.5) | 293 (2.6) | 393 (3.4) | 47 (0.4) | 9 (0.1) |
| Northern Europe | 3126 (9.5) | 1981 (63.4) | 744 (23.8) | 223 (7.1) | 99 (3.2) | 65 (2.1) | 8 (0.3) | 6 (0.2) |
| South-East Europe | 1901 (5.8) | 838 (44.1) | 446 (23.5) | 299 (15.7) | 124 (6.5) | 178 (9.4) | 13 (0.7) | 3 (0.2) |
| Western Europe | 12090 (36.7) | 8073 (66.8) | 2146 (17.8) | 847 (7) | 411 (3.4) | 392 (3.2) | 44 (0.4) | 177 (1.5) |
| Migrants, N (%) | | | | | | | | |

Description of the sample using all vaccine acceptance question items. (*continued*)

| Question | Sample Description | I will get vaccinated | Probably yes | Not sure | Probably not | I won't get vaccinated | Prefer not to answer | Missing |
|---|--------------------|-----------------------|--------------|------------|--------------|------------------------|----------------------|-----------|
| No | 27524 (83.7) | 16567 (60.2) | 5833 (21.2) | 2532 (9.2) | 1069 (3.9) | 1260 (4.6) | 111 (0.4) | 152 (0.6) |
| Yes | 5378 (16.3) | 3699 (68.8) | 881 (16.4) | 358 (6.7) | 167 (3.1) | 190 (3.5) | 34 (0.6) | 49 (0.9) |
| Migrant Origin, N (%) | | | | | | | | |
| Baltics | 47 (0.9) | 31 (66) | 8 (17) | 3 (6.4) | 3 (6.4) | 1 (2.1) | 1 (2.1) | 0 (0) |
| Caribbean | 86 (1.6) | 64 (74.4) | 11 (12.8) | 5 (5.8) | 1 (1.2) | 1 (1.2) | 2 (2.3) | 2 (2.3) |
| Central America | 150 (2.8) | 129 (86) | 12 (8) | 2 (1.3) | 3 (2) | 3 (2) | 0 (0) | 1 (0.7) |
| Central Europe | 420 (7.8) | 232 (55.2) | 80 (19) | 53 (12.6) | 19 (4.5) | 27 (6.4) | 8 (1.9) | 1 (0.2) |
| Eastern Europe | 292 (5.4) | 126 (43.2) | 83 (28.4) | 38 (13) | 21 (7.2) | 20 (6.8) | 4 (1.4) | 0 (0) |
| Eastern Mediterranean | 254 (4.7) | 172 (67.7) | 40 (15.7) | 20 (7.9) | 7 (2.8) | 10 (3.9) | 4 (1.6) | 1 (0.4) |
| Mediterranean | 713 (13.3) | 506 (71) | 111 (15.6) | 45 (6.3) | 19 (2.7) | 25 (3.5) | 1 (0.1) | 6 (0.8) |
| Europe Northern America | 210 (3.9) | 158 (75.2) | 31 (14.8) | 8 (3.8) | 5 (2.4) | 8 (3.8) | 0 (0) | 0 (0) |
| Northern Europe | 130 (2.4) | 89 (68.5) | 26 (20) | 9 (6.9) | 2 (1.5) | 4 (3.1) | 0 (0) | 0 (0) |
| South America | 1241 (23.1) | 988 (79.6) | 169 (13.6) | 49 (3.9) | 13 (1) | 16 (1.3) | 4 (0.3) | 2 (0.2) |
| South-East Asia | 67 (1.2) | 37 (55.2) | 15 (22.4) | 9 (13.4) | 1 (1.5) | 3 (4.5) | 2 (3) | 0 (0) |
| South-East Europe | 315 (5.9) | 169 (53.7) | 63 (20) | 36 (11.4) | 18 (5.7) | 26 (8.3) | 2 (0.6) | 1 (0.3) |
| Sub-Saharan Africa | 166 (3.1) | 110 (66.3) | 26 (15.7) | 14 (8.4) | 5 (3) | 7 (4.2) | 3 (1.8) | 1 (0.6) |
| Western Europe | 1037 (19.3) | 723 (69.7) | 163 (15.7) | 58 (5.6) | 45 (4.3) | 38 (3.7) | 1 (0.1) | 9 (0.9) |
| Western Pacific | 155 (2.9) | 112 (72.3) | 30 (19.4) | 7 (4.5) | 2 (1.3) | 1 (0.6) | 2 (1.3) | 1 (0.6) |
| Unclear Region | 95 (1.8) | 53 (55.8) | 13 (13.7) | 2 (2.1) | 3 (3.2) | 0 (0) | 0 (0) | 24 (25.3) |
| HIV, N (%) | | | | | | | | |
| HIV- | 27585 (83.8) | 16732 (60.7) | 5806 (21) | 2467 (8.9) | 1095 (4) | 1208 (4.4) | 105 (0.4) | 172 (0.6) |
| HIV+ on ART | 3780 (11.5) | 2764 (73.1) | 571 (15.1) | 209 (5.5) | 79 (2.1) | 129 (3.4) | 9 (0.2) | 19 (0.5) |
| HIV+ not on ART | 123 (0.4) | 71 (57.7) | 21 (17.1) | 10 (8.1) | 5 (4.1) | 15 (12.2) | 1 (0.8) | 0 (0) |
| HIV status unknown | 989 (3) | 469 (47.4) | 240 (24.3) | 156 (15.8) | 46 (4.7) | 65 (6.6) | 11 (1.1) | 2 (0.2) |
| Prefer not to answer | 339 (1) | 177 (52.2) | 65 (19.2) | 40 (11.8) | 8 (2.4) | 29 (8.6) | 19 (5.6) | 1 (0.3) |
| Missing | 86 (0.3) | 53 (61.6) | 11 (12.8) | 8 (9.3) | 3 (3.5) | 4 (4.7) | 0 (0) | 7 (8.1) |
| PrEP, N (%) | | | | | | | | |
| PrEP no | 21526 (74.2) | 11554 (53.7) | 5273 (24.5) | 2364 (11) | 1030 (4.8) | 1138 (5.3) | 104 (0.5) | 63 (0.3) |
| PrEP yes | 7210 (24.9) | 5742 (79.6) | 801 (11.1) | 275 (3.8) | 111 (1.5) | 150 (2.1) | 25 (0.3) | 106 (1.5) |
| Missing | 263 (0.9) | 135 (51.3) | 48 (18.3) | 32 (12.2) | 11 (4.2) | 18 (6.8) | 6 (2.3) | 13 (4.9) |
| STI in the last 12 months, N (%) | | | | | | | | |
| STI no | 26059 (79.2) | 15263 (58.6) | 5694 (21.9) | 2493 (9.6) | 1099 (4.2) | 1291 (5) | 110 (0.4) | 109 (0.4) |
| STI yes | 6156 (18.7) | 4669 (75.8) | 852 (13.8) | 308 (5) | 108 (1.8) | 123 (2) | 17 (0.3) | 79 (1.3) |
| STI unknown | 474 (1.4) | 227 (47.9) | 129 (27.2) | 65 (13.7) | 26 (5.5) | 20 (4.2) | 7 (1.5) | 0 (0) |
| Prefer not to answer | 111 (0.3) | 55 (49.5) | 19 (17.1) | 14 (12.6) | 1 (0.9) | 11 (9.9) | 10 (9) | 1 (0.9) |

Description of the sample using all vaccine acceptance question items. (*continued*)

| Question | Sample Description | I will get vaccinated | Probably yes | Not sure | Probably not | I won't get vaccinated | Prefer not to answer | Missing |
|--|--------------------|-----------------------|--------------|------------|--------------|------------------------|----------------------|-----------|
| Missing | 102 (0.3) | 52 (51) | 20 (19.6) | 10 (9.8) | 2 (2) | 5 (4.9) | 1 (1) | 12 (11.8) |
| Chemsex users, N (%) | | | | | | | | |
| Chemsex no | 29723 (90.3) | 17988 (60.5) | 6282 (21.1) | 2750 (9.3) | 1165 (3.9) | 1300 (4.4) | 117 (0.4) | 121 (0.4) |
| Chemsex yes | 2892 (8.8) | 2117 (73.2) | 386 (13.3) | 123 (4.3) | 66 (2.3) | 129 (4.5) | 8 (0.3) | 63 (2.2) |
| Prefer not to answer | 241 (0.7) | 136 (56.4) | 42 (17.4) | 16 (6.6) | 4 (1.7) | 20 (8.3) | 20 (8.3) | 3 (1.2) |
| Missing | 46 (0.1) | 25 (54.3) | 4 (8.7) | 1 (2.2) | 1 (2.2) | 1 (2.2) | 0 (0) | 14 (30.4) |
| Perception of risk to get MPX, N (%) | | | | | | | | |
| Not worried | 4211 (12.8) | 1212 (28.8) | 875 (20.8) | 630 (15) | 523 (12.4) | 939 (22.3) | 20 (0.5) | 12 (0.3) |
| Slightly worried | 7277 (22.1) | 3657 (50.3) | 2039 (28) | 907 (12.5) | 373 (5.1) | 240 (3.3) | 21 (0.3) | 40 (0.5) |
| Moderately worried | 7232 (22) | 4520 (62.5) | 1701 (23.5) | 658 (9.1) | 183 (2.5) | 112 (1.5) | 16 (0.2) | 42 (0.6) |
| Worried | 8269 (25.1) | 6173 (74.7) | 1454 (17.6) | 390 (4.7) | 88 (1.1) | 69 (0.8) | 19 (0.2) | 76 (0.9) |
| Very worried | 5243 (15.9) | 4498 (85.8) | 506 (9.7) | 143 (2.7) | 37 (0.7) | 41 (0.8) | 12 (0.2) | 6 (0.1) |
| I don't know | 630 (1.9) | 194 (30.8) | 136 (21.6) | 161 (25.6) | 31 (4.9) | 49 (7.8) | 57 (9) | 2 (0.3) |
| Missing | 40 (0.1) | 12 (30) | 3 (7.5) | 1 (2.5) | 1 (2.5) | 0 (0) | 0 (0) | 23 (57.5) |
| Perception of MPX severity, N (%) | | | | | | | | |
| Not severe | 1282 (3.9) | 392 (30.6) | 135 (10.5) | 118 (9.2) | 127 (9.9) | 498 (38.8) | 9 (0.7) | 3 (0.2) |
| Slightly severe | 3874 (11.8) | 1982 (51.2) | 830 (21.4) | 443 (11.4) | 284 (7.3) | 302 (7.8) | 11 (0.3) | 22 (0.6) |
| Moderately severe | 10170 (30.9) | 6160 (60.6) | 2335 (23) | 991 (9.7) | 393 (3.9) | 241 (2.4) | 19 (0.2) | 31 (0.3) |
| Severe | 10373 (31.5) | 7167 (69.1) | 2108 (20.3) | 634 (6.1) | 200 (1.9) | 135 (1.3) | 22 (0.2) | 107 (1) |
| Very severe | 4586 (13.9) | 3657 (79.7) | 618 (13.5) | 171 (3.7) | 49 (1.1) | 57 (1.2) | 18 (0.4) | 16 (0.3) |
| I don't know | 2581 (7.8) | 902 (34.9) | 683 (26.5) | 531 (20.6) | 181 (7) | 217 (8.4) | 66 (2.6) | 1 (0) |
| Missing | 36 (0.1) | 6 (16.7) | 5 (13.9) | 2 (5.6) | 2 (5.6) | 0 (0) | 0 (0) | 21 (58.3) |
| Know someone or diagnosed with MPX, N (%) | | | | | | | | |
| No | 26081 (79.3) | 15085 (57.8) | 5830 (22.4) | 2550 (9.8) | 1113 (4.3) | 1295 (5) | 98 (0.4) | 110 (0.4) |
| Yes, only me | 232 (0.7) | 175 (75.4) | 29 (12.5) | 7 (3) | 6 (2.6) | 11 (4.7) | 2 (0.9) | 2 (0.9) |
| Yes, me and someone I know | 619 (1.9) | 495 (80) | 66 (10.7) | 23 (3.7) | 9 (1.5) | 19 (3.1) | 4 (0.6) | 3 (0.5) |
| Yes, only someone I know | 3830 (11.6) | 3180 (83) | 365 (9.5) | 117 (3.1) | 43 (1.1) | 59 (1.5) | 8 (0.2) | 58 (1.5) |
| I don't know | 2018 (6.1) | 1277 (63.3) | 413 (20.5) | 184 (9.1) | 63 (3.1) | 59 (2.9) | 16 (0.8) | 6 (0.3) |
| Prefer not to answer | 83 (0.3) | 43 (51.8) | 10 (12) | 6 (7.2) | 2 (2.4) | 5 (6) | 17 (20.5) | 0 (0) |
| Missing | 39 (0.1) | 11 (28.2) | 1 (2.6) | 3 (7.7) | 0 (0) | 2 (5.1) | 0 (0) | 22 (56.4) |

Description of the sample using all vaccine acceptance question items. (*continued*)

| Question | Sample Description | I will get vaccinated | Probably yes | Not sure | Probably not | I won't get vaccinated | Prefer not to answer | Missing |
|--|--------------------|-----------------------|--------------|-------------|--------------|------------------------|----------------------|-----------|
| Perception of vaccine protection in general, N (%) | | | | | | | | |
| Strongly disagree | 1293 (4) | 715 (55.3) | 209 (16.2) | 92 (7.1) | 42 (3.2) | 228 (17.6) | 6 (0.5) | 1 (0.1) |
| Slightly disagree | 702 (2.2) | 116 (16.5) | 146 (20.8) | 152 (21.7) | 80 (11.4) | 200 (28.5) | 6 (0.9) | 2 (0.3) |
| Neither disagree nor agree | 951 (3) | 112 (11.8) | 156 (16.4) | 249 (26.2) | 159 (16.7) | 247 (26) | 26 (2.7) | 2 (0.2) |
| Slightly agree | 7139 (22.2) | 3356 (47) | 1777 (24.9) | 1046 (14.7) | 478 (6.7) | 441 (6.2) | 32 (0.4) | 9 (0.1) |
| Strongly agree | 21590 (67.3) | 15414 (71.4) | 4237 (19.6) | 1212 (5.6) | 414 (1.9) | 263 (1.2) | 37 (0.2) | 13 (0.1) |
| I don't know | 401 (1.2) | 80 (20) | 89 (22.2) | 107 (26.7) | 31 (7.7) | 54 (13.5) | 38 (9.5) | 2 (0.5) |
| Missing | 24 (0.1) | 4 (16.7) | 4 (16.7) | 2 (8.3) | 1 (4.2) | 0 (0) | 0 (0) | 13 (54.2) |
| Worried about being treated differently due to MPX, N (%) | | | | | | | | |
| No | 12245 (38.1) | 6640 (54.2) | 2723 (22.2) | 1228 (10) | 658 (5.4) | 940 (7.7) | 51 (0.4) | 5 (0) |
| Yes | 11558 (36) | 8273 (71.6) | 2043 (17.7) | 749 (6.5) | 279 (2.4) | 193 (1.7) | 19 (0.2) | 2 (0) |
| I don't know | 5310 (16.5) | 2858 (53.8) | 1371 (25.8) | 661 (12.4) | 207 (3.9) | 187 (3.5) | 21 (0.4) | 5 (0.1) |
| Prefer not to answer | 257 (0.8) | 82 (31.9) | 50 (19.5) | 38 (14.8) | 17 (6.6) | 21 (8.2) | 49 (19.1) | 0 (0) |
| Missing | 2730 (8.5) | 1944 (71.2) | 431 (15.8) | 184 (6.7) | 44 (1.6) | 92 (3.4) | 5 (0.2) | 30 (1.1) |

S4. Description of the sample by region

The following tables describe the survey sample stratified by European subregion or residence of the respondents. See the manuscript for the description of the table.

Central Europe

Description of the sample for the Central Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|----------------|-------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 2628 (100) | 1760 (67) | 376 (14.3) | 472 (18) | 20 (0.8) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 176 (7.4) | 134 (76.1) | 28 (15.9) | 14 (8) | 0 (0) |
| With my general practitioner | 340 (14.3) | 235 (69.1) | 62 (18.2) | 41 (12.1) | 2 (0.6) |
| In a community-based centre | 207 (8.7) | 160 (77.3) | 31 (15) | 16 (7.7) | 0 (0) |
| In a vaccination program centre | 504 (21.2) | 386 (76.6) | 85 (16.9) | 31 (6.2) | 2 (0.4) |
| It doesn't matter | 953 (40.2) | 765 (80.3) | 124 (13) | 64 (6.7) | 0 (0) |
| I don't know | 180 (7.6) | 76 (42.2) | 46 (25.6) | 45 (25) | 13 (7.2) |
| Missing | 12 (0.5) | 4 (33.3) | 0 (0) | 5 (41.7) | 3 (25) |
| Age, Median (IQR) | 33.0 (26 - 41) | 34.0 (26 - 42) | 31.0 (24 - 38) | 33.0 (26 - 41) | 35.0 (26.75 - 41) |
| Age category, N (%) | | | | | |
| 18-29 | 975 (37.1) | 633 (64.9) | 170 (17.4) | 166 (17) | 6 (0.6) |
| 30-39 | 851 (32.4) | 563 (66.2) | 121 (14.2) | 160 (18.8) | 7 (0.8) |
| 40-49 | 609 (23.2) | 421 (69.1) | 67 (11) | 115 (18.9) | 6 (1) |
| 50-84 | 193 (7.3) | 143 (74.1) | 18 (9.3) | 31 (16.1) | 1 (0.5) |
| Region of residence, N (%) | | | | | |
| Central Europe | 2628 (100) | 1760 (67) | 376 (14.3) | 472 (18) | 20 (0.8) |
| Migrants, N (%) | | | | | |
| No | 2439 (92.8) | 1641 (67.3) | 350 (14.4) | 432 (17.7) | 16 (0.7) |
| Yes | 189 (7.2) | 119 (63) | 26 (13.8) | 40 (21.2) | 4 (2.1) |
| Migrant Origin, N (%) | | | | | |
| Baltics | 5 (2.6) | 5 (100) | 0 (0) | 0 (0) | 0 (0) |
| Central America | 3 (1.6) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) |
| Central Europe | 79 (41.8) | 47 (59.5) | 12 (15.2) | 18 (22.8) | 2 (2.5) |
| Eastern Europe | 37 (19.6) | 20 (54.1) | 7 (18.9) | 10 (27) | 0 (0) |
| Eastern | 4 (2.1) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| Mediterranean | 11 (5.8) | 7 (63.6) | 2 (18.2) | 2 (18.2) | 0 (0) |
| Europe | | | | | |
| Northern Europe | 2 (1.1) | 0 (0) | 0 (0) | 2 (100) | 0 (0) |
| South America | 5 (2.6) | 5 (100) | 0 (0) | 0 (0) | 0 (0) |
| South-East Asia | 2 (1.1) | 2 (100) | 0 (0) | 0 (0) | 0 (0) |
| South-East Europe | 13 (6.9) | 8 (61.5) | 1 (7.7) | 3 (23.1) | 1 (7.7) |
| Western Europe | 23 (12.2) | 16 (69.6) | 3 (13) | 4 (17.4) | 0 (0) |
| Western Pacific | 5 (2.6) | 3 (60) | 1 (20) | 0 (0) | 1 (20) |
| HIV, N (%) | | | | | |
| HIV- | 2192 (83.4) | 1456 (66.4) | 324 (14.8) | 399 (18.2) | 13 (0.6) |
| HIV+ on ART | 268 (10.2) | 206 (76.9) | 25 (9.3) | 36 (13.4) | 1 (0.4) |
| HIV+ not on ART | 17 (0.6) | 12 (70.6) | 1 (5.9) | 4 (23.5) | 0 (0) |

Description of the sample for the Central Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|---|--------------------|-------------|------------|------------|-------------------|
| HIV status unknown | 115 (4.4) | 64 (55.7) | 22 (19.1) | 26 (22.6) | 3 (2.6) |
| Prefer not to answer | 34 (1.3) | 21 (61.8) | 3 (8.8) | 7 (20.6) | 3 (8.8) |
| Missing | 2 (0.1) | 1 (50) | 1 (50) | 0 (0) | 0 (0) |
| PrEP, N (%) | | | | | |
| PrEP no | 2009 (85.7) | 1277 (63.6) | 320 (15.9) | 397 (19.8) | 15 (0.7) |
| PrEP yes | 321 (13.7) | 256 (79.8) | 28 (8.7) | 33 (10.3) | 4 (1.2) |
| Missing | 13 (0.6) | 9 (69.2) | 2 (15.4) | 2 (15.4) | 0 (0) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 2251 (85.7) | 1471 (65.3) | 339 (15.1) | 425 (18.9) | 16 (0.7) |
| STI yes | 266 (10.1) | 212 (79.7) | 23 (8.6) | 31 (11.7) | 0 (0) |
| STI unknown | 36 (1.4) | 23 (63.9) | 5 (13.9) | 7 (19.4) | 1 (2.8) |
| Prefer not to answer | 14 (0.5) | 7 (50) | 1 (7.1) | 3 (21.4) | 3 (21.4) |
| Missing | 61 (2.3) | 47 (77) | 8 (13.1) | 6 (9.8) | 0 (0) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 2340 (89) | 1551 (66.3) | 356 (15.2) | 420 (17.9) | 13 (0.6) |
| Chemsex yes | 253 (9.6) | 187 (73.9) | 17 (6.7) | 47 (18.6) | 2 (0.8) |
| Prefer not to answer | 32 (1.2) | 20 (62.5) | 3 (9.4) | 4 (12.5) | 5 (15.6) |
| Missing | 3 (0.1) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) |
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 616 (23.4) | 231 (37.5) | 105 (17) | 277 (45) | 3 (0.5) |
| Slightly worried | 732 (27.9) | 518 (70.8) | 120 (16.4) | 90 (12.3) | 4 (0.5) |
| Moderately worried | 494 (18.8) | 375 (75.9) | 70 (14.2) | 49 (9.9) | 0 (0) |
| Worried | 474 (18) | 431 (90.9) | 26 (5.5) | 17 (3.6) | 0 (0) |
| Very worried | 172 (6.5) | 152 (88.4) | 8 (4.7) | 11 (6.4) | 1 (0.6) |
| I don't know | 136 (5.2) | 51 (37.5) | 47 (34.6) | 28 (20.6) | 10 (7.4) |
| Missing | 4 (0.2) | 2 (50) | 0 (0) | 0 (0) | 2 (50) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 168 (6.4) | 33 (19.6) | 18 (10.7) | 114 (67.9) | 3 (1.8) |
| Slightly severe | 316 (12) | 164 (51.9) | 49 (15.5) | 102 (32.3) | 1 (0.3) |
| Moderately severe | 770 (29.3) | 545 (70.8) | 122 (15.8) | 102 (13.2) | 1 (0.1) |
| Severe | 769 (29.3) | 640 (83.2) | 83 (10.8) | 45 (5.9) | 1 (0.1) |
| Very severe | 226 (8.6) | 196 (86.7) | 13 (5.8) | 16 (7.1) | 1 (0.4) |
| I don't know | 374 (14.2) | 180 (48.1) | 91 (24.3) | 92 (24.6) | 11 (2.9) |
| Missing | 5 (0.2) | 2 (40) | 0 (0) | 1 (20) | 2 (40) |
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 2357 (89.7) | 1565 (66.4) | 346 (14.7) | 433 (18.4) | 13 (0.6) |
| Yes, only me | 13 (0.5) | 6 (46.2) | 2 (15.4) | 5 (38.5) | 0 (0) |
| Yes, me and someone I know | 9 (0.3) | 6 (66.7) | 1 (11.1) | 1 (11.1) | 1 (11.1) |
| Yes, only someone I know | 110 (4.2) | 90 (81.8) | 8 (7.3) | 11 (10) | 1 (0.9) |
| I don't know | 131 (5) | 93 (71) | 17 (13) | 21 (16) | 0 (0) |
| Prefer not to answer | 6 (0.2) | 0 (0) | 2 (33.3) | 1 (16.7) | 3 (50) |
| Missing | 2 (0.1) | 0 (0) | 0 (0) | 0 (0) | 2 (100) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 222 (8.4) | 136 (61.3) | 14 (6.3) | 71 (32) | 1 (0.5) |
| Slightly disagree | 108 (4.1) | 24 (22.2) | 23 (21.3) | 60 (55.6) | 1 (0.9) |

Description of the sample for the Central Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|------------|------------|-------------------|
| Neither disagree nor agree | 132 (5) | 22 (16.7) | 39 (29.5) | 68 (51.5) | 3 (2.3) |
| Slightly agree | 430 (16.4) | 186 (43.3) | 110 (25.6) | 130 (30.2) | 4 (0.9) |
| Strongly agree | 1694 (64.5) | 1383 (81.6) | 180 (10.6) | 127 (7.5) | 4 (0.2) |
| I don't know | 41 (1.6) | 9 (22) | 10 (24.4) | 16 (39) | 6 (14.6) |
| Missing | 1 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 1148 (43.7) | 681 (59.3) | 186 (16.2) | 278 (24.2) | 3 (0.3) |
| Yes | 770 (29.3) | 620 (80.5) | 74 (9.6) | 75 (9.7) | 1 (0.1) |
| I don't know | 621 (23.6) | 438 (70.5) | 109 (17.6) | 71 (11.4) | 3 (0.5) |
| Prefer not to answer | 39 (1.5) | 18 (46.2) | 7 (17.9) | 4 (10.3) | 10 (25.6) |
| Missing | 50 (1.9) | 3 (6) | 0 (0) | 44 (88) | 3 (6) |

South-East Europe

Description of the sample for the South-East Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|----------------|-------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 1901 (100) | 1284 (67.5) | 299 (15.7) | 302 (15.9) | 16 (0.8) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 219 (12.7) | 167 (76.3) | 42 (19.2) | 8 (3.7) | 2 (0.9) |
| With my general practitioner | 214 (12.4) | 147 (68.7) | 50 (23.4) | 15 (7) | 2 (0.9) |
| In a community-based centre | 132 (7.7) | 100 (75.8) | 22 (16.7) | 10 (7.6) | 0 (0) |
| In a vaccination program centre | 351 (20.4) | 253 (72.1) | 71 (20.2) | 26 (7.4) | 1 (0.3) |
| It doesn't matter | 674 (39.1) | 579 (85.9) | 69 (10.2) | 24 (3.6) | 2 (0.3) |
| I don't know | 116 (6.7) | 31 (26.7) | 42 (36.2) | 37 (31.9) | 6 (5.2) |
| Missing | 17 (1) | 7 (41.2) | 3 (17.6) | 4 (23.5) | 3 (17.6) |
| Age, Median (IQR) | 33.0 (27 - 40) | 34.0 (27 - 41) | 32.0 (25 - 39) | 32.0 (26 - 40) | 31.5 (24.75 - 38) |
| Age category, N (%) | | | | | |
| 18-29 | 686 (36.1) | 438 (63.8) | 126 (18.4) | 115 (16.8) | 7 (1) |
| 30-39 | 679 (35.7) | 469 (69.1) | 102 (15) | 103 (15.2) | 5 (0.7) |
| 40-49 | 396 (20.8) | 277 (69.9) | 55 (13.9) | 63 (15.9) | 1 (0.3) |
| 50-84 | 140 (7.4) | 100 (71.4) | 16 (11.4) | 21 (15) | 3 (2.1) |
| Region of residence, N (%) | | | | | |
| South-East Europe | 1901 (100) | 1284 (67.5) | 299 (15.7) | 302 (15.9) | 16 (0.8) |
| Migrants, N (%) | | | | | |
| No | 1721 (90.5) | 1159 (67.3) | 278 (16.2) | 269 (15.6) | 15 (0.9) |
| Yes | 180 (9.5) | 125 (69.4) | 21 (11.7) | 33 (18.3) | 1 (0.6) |
| Migrant Origin, N (%) | | | | | |
| Caribbean | 1 (0.6) | 1 (100) | 0 (0) | 0 (0) | 0 (0) |
| Central Europe | 6 (3.3) | 2 (33.3) | 1 (16.7) | 3 (50) | 0 (0) |
| Eastern Europe | 15 (8.3) | 11 (73.3) | 1 (6.7) | 3 (20) | 0 (0) |
| Eastern Mediterranean | 25 (13.9) | 21 (84) | 3 (12) | 1 (4) | 0 (0) |

Description of the sample for the South-East Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|------------|------------|-------------------|
| Mediterranean Europe | 10 (5.6) | 5 (50) | 2 (20) | 3 (30) | 0 (0) |
| Northern America | 7 (3.9) | 7 (100) | 0 (0) | 0 (0) | 0 (0) |
| South America | 6 (3.3) | 5 (83.3) | 0 (0) | 1 (16.7) | 0 (0) |
| South-East Asia | 2 (1.1) | 1 (50) | 1 (50) | 0 (0) | 0 (0) |
| South-East Europe | 74 (41.1) | 49 (66.2) | 9 (12.2) | 16 (21.6) | 0 (0) |
| Sub-Saharan Africa | 4 (2.2) | 3 (75) | 0 (0) | 0 (0) | 1 (25) |
| Western Europe | 28 (15.6) | 18 (64.3) | 4 (14.3) | 6 (21.4) | 0 (0) |
| Western Pacific | 2 (1.1) | 2 (100) | 0 (0) | 0 (0) | 0 (0) |
| HIV, N (%) | | | | | |
| HIV- | 1478 (77.7) | 977 (66.1) | 242 (16.4) | 249 (16.8) | 10 (0.7) |
| HIV+ on ART | 238 (12.5) | 190 (79.8) | 24 (10.1) | 22 (9.2) | 2 (0.8) |
| HIV+ not on ART | 13 (0.7) | 7 (53.8) | 4 (30.8) | 2 (15.4) | 0 (0) |
| HIV status unknown | 129 (6.8) | 82 (63.6) | 22 (17.1) | 22 (17.1) | 3 (2.3) |
| Prefer not to answer | 32 (1.7) | 21 (65.6) | 7 (21.9) | 4 (12.5) | 0 (0) |
| Missing | 11 (0.6) | 7 (63.6) | 0 (0) | 3 (27.3) | 1 (9.1) |
| PrEP, N (%) | | | | | |
| PrEP no | 1421 (86.1) | 926 (65.2) | 246 (17.3) | 240 (16.9) | 9 (0.6) |
| PrEP yes | 201 (12.2) | 145 (72.1) | 22 (10.9) | 31 (15.4) | 3 (1.5) |
| Missing | 28 (1.7) | 16 (57.1) | 3 (10.7) | 7 (25) | 2 (7.1) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 1565 (82.3) | 1035 (66.1) | 254 (16.2) | 265 (16.9) | 11 (0.7) |
| STI yes | 260 (13.7) | 201 (77.3) | 34 (13.1) | 23 (8.8) | 2 (0.8) |
| STI unknown | 60 (3.2) | 36 (60) | 9 (15) | 13 (21.7) | 2 (3.3) |
| Prefer not to answer | 12 (0.6) | 10 (83.3) | 1 (8.3) | 1 (8.3) | 0 (0) |
| Missing | 4 (0.2) | 2 (50) | 1 (25) | 0 (0) | 1 (25) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 1681 (88.4) | 1107 (65.9) | 283 (16.8) | 282 (16.8) | 9 (0.5) |
| Chemsex yes | 193 (10.2) | 162 (83.9) | 14 (7.3) | 15 (7.8) | 2 (1) |
| Prefer not to answer | 26 (1.4) | 15 (57.7) | 2 (7.7) | 5 (19.2) | 4 (15.4) |
| Missing | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 322 (16.9) | 118 (36.6) | 47 (14.6) | 155 (48.1) | 2 (0.6) |
| Slightly worried | 488 (25.7) | 321 (65.8) | 95 (19.5) | 71 (14.5) | 1 (0.2) |
| Moderately worried | 405 (21.3) | 299 (73.8) | 67 (16.5) | 35 (8.6) | 4 (1) |
| Worried | 404 (21.3) | 336 (83.2) | 46 (11.4) | 20 (5) | 2 (0.5) |
| Very worried | 200 (10.5) | 170 (85) | 20 (10) | 10 (5) | 0 (0) |
| I don't know | 80 (4.2) | 40 (50) | 24 (30) | 11 (13.8) | 5 (6.2) |
| Missing | 2 (0.1) | 0 (0) | 0 (0) | 0 (0) | 2 (100) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 97 (5.1) | 22 (22.7) | 20 (20.6) | 55 (56.7) | 0 (0) |
| Slightly severe | 265 (13.9) | 156 (58.9) | 42 (15.8) | 66 (24.9) | 1 (0.4) |
| Moderately severe | 592 (31.1) | 421 (71.1) | 96 (16.2) | 71 (12) | 4 (0.7) |
| Severe | 324 (17) | 255 (78.7) | 36 (11.1) | 31 (9.6) | 2 (0.6) |
| Very severe | 293 (15.4) | 243 (82.9) | 34 (11.6) | 15 (5.1) | 1 (0.3) |
| I don't know | 328 (17.3) | 187 (57) | 71 (21.6) | 64 (19.5) | 6 (1.8) |
| Missing | 2 (0.1) | 0 (0) | 0 (0) | 0 (0) | 2 (100) |
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 1686 (88.7) | 1131 (67.1) | 269 (16) | 275 (16.3) | 11 (0.7) |

Description of the sample for the South-East Europe subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|------------|------------|------------|-------------------|
| Yes, only me | 7 (0.4) | 5 (71.4) | 0 (0) | 1 (14.3) | 1 (14.3) |
| Yes, me and someone I know | 6 (0.3) | 6 (100) | 0 (0) | 0 (0) | 0 (0) |
| Yes, only someone I know | 72 (3.8) | 59 (81.9) | 5 (6.9) | 8 (11.1) | 0 (0) |
| I don't know | 121 (6.4) | 81 (66.9) | 23 (19) | 17 (14) | 0 (0) |
| Prefer not to answer | 5 (0.3) | 1 (20) | 1 (20) | 1 (20) | 2 (40) |
| Missing | 4 (0.2) | 1 (25) | 1 (25) | 0 (0) | 2 (50) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 269 (14.2) | 191 (71) | 26 (9.7) | 51 (19) | 1 (0.4) |
| Slightly disagree | 129 (6.8) | 49 (38) | 34 (26.4) | 46 (35.7) | 0 (0) |
| Neither disagree nor agree | 136 (7.2) | 25 (18.4) | 49 (36) | 59 (43.4) | 3 (2.2) |
| Slightly agree | 417 (21.9) | 210 (50.4) | 105 (25.2) | 97 (23.3) | 5 (1.2) |
| Strongly agree | 897 (47.2) | 792 (88.3) | 62 (6.9) | 41 (4.6) | 2 (0.2) |
| I don't know | 50 (2.6) | 17 (34) | 21 (42) | 8 (16) | 4 (8) |
| Missing | 3 (0.2) | 0 (0) | 2 (66.7) | 0 (0) | 1 (33.3) |
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 615 (32.4) | 339 (55.1) | 103 (16.7) | 168 (27.3) | 5 (0.8) |
| Yes | 849 (44.7) | 676 (79.6) | 108 (12.7) | 64 (7.5) | 1 (0.1) |
| I don't know | 409 (21.5) | 258 (63.1) | 84 (20.5) | 64 (15.6) | 3 (0.7) |
| Prefer not to answer | 25 (1.3) | 10 (40) | 4 (16) | 6 (24) | 5 (20) |
| Missing | 3 (0.2) | 1 (33.3) | 0 (0) | 0 (0) | 2 (66.7) |

Baltics

Description of the sample for the Baltics subregion.

| Question | Sample Description | MPX Vaccine acceptance | | |
|---|--------------------|------------------------|--------------------|----------------------|
| | | Acceptance | Hesitancy | Refusal |
| Total, N (%) | 131 (100) | 106 (80.9) | 15 (11.5) | 10 (7.6) |
| Preferred place to get vaccinated, N (%) | | | | |
| In an STI clinic | 10 (7.9) | 9 (90) | 1 (10) | 0 (0) |
| With my general practitioner | 16 (12.6) | 13 (81.2) | 3 (18.8) | 0 (0) |
| In a community-based centre | 3 (2.4) | 3 (100) | 0 (0) | 0 (0) |
| In a vaccination program centre | 23 (18.1) | 21 (91.3) | 1 (4.3) | 1 (4.3) |
| It doesn't matter | 69 (54.3) | 59 (85.5) | 6 (8.7) | 4 (5.8) |
| I don't know | 6 (4.7) | 1 (16.7) | 4 (66.7) | 1 (16.7) |
| Age, Median (IQR) | 34.0 (28.5 - 41) | 34.0 (29 - 40) | 32.0 (26.5 - 44.5) | 35.0 (26.25 - 39.25) |
| Age category, N (%) | | | | |
| 18-29 | 38 (29) | 30 (78.9) | 5 (13.2) | 3 (7.9) |
| 30-39 | 56 (42.7) | 47 (83.9) | 5 (8.9) | 4 (7.1) |
| 40-49 | 25 (19.1) | 20 (80) | 3 (12) | 2 (8) |
| 50-84 | 12 (9.2) | 9 (75) | 2 (16.7) | 1 (8.3) |
| Region of residence, N (%) | | | | |
| Baltics | 131 (100) | 106 (80.9) | 15 (11.5) | 10 (7.6) |

Description of the sample for the Baltics subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal |
|--|--------------------|------------|-----------|----------|
| Migrants, N (%) | | | | |
| No | 97 (74) | 76 (78.4) | 13 (13.4) | 8 (8.2) |
| Yes | 34 (26) | 30 (88.2) | 2 (5.9) | 2 (5.9) |
| Migrant Origin, N (%) | | | | |
| Baltics | 2 (5.9) | 1 (50) | 0 (0) | 1 (50) |
| Central Europe | 1 (2.9) | 1 (100) | 0 (0) | 0 (0) |
| Eastern Europe | 15 (44.1) | 13 (86.7) | 1 (6.7) | 1 (6.7) |
| Eastern Mediterranean | 1 (2.9) | 1 (100) | 0 (0) | 0 (0) |
| Mediterranean Europe | 4 (11.8) | 4 (100) | 0 (0) | 0 (0) |
| Northern America | 3 (8.8) | 3 (100) | 0 (0) | 0 (0) |
| Northern Europe | 4 (11.8) | 3 (75) | 1 (25) | 0 (0) |
| Western Europe | 2 (5.9) | 2 (100) | 0 (0) | 0 (0) |
| Western Pacific | 2 (5.9) | 2 (100) | 0 (0) | 0 (0) |
| HIV, N (%) | | | | |
| HIV- | 116 (88.5) | 98 (84.5) | 9 (7.8) | 9 (7.8) |
| HIV+ on ART | 7 (5.3) | 4 (57.1) | 3 (42.9) | 0 (0) |
| HIV+ not on ART | 1 (0.8) | 1 (100) | 0 (0) | 0 (0) |
| HIV status unknown | 3 (2.3) | 2 (66.7) | 1 (33.3) | 0 (0) |
| Prefer not to answer | 2 (1.5) | 1 (50) | 1 (50) | 0 (0) |
| Missing | 2 (1.5) | 0 (0) | 1 (50) | 1 (50) |
| PrEP, N (%) | | | | |
| PrEP no | 100 (81.3) | 80 (80) | 11 (11) | 9 (9) |
| PrEP yes | 20 (16.3) | 20 (100) | 0 (0) | 0 (0) |
| Missing | 3 (2.4) | 1 (33.3) | 1 (33.3) | 1 (33.3) |
| STI in the last 12 months, N (%) | | | | |
| STI no | 114 (87) | 91 (79.8) | 14 (12.3) | 9 (7.9) |
| STI yes | 16 (12.2) | 14 (87.5) | 1 (6.2) | 1 (6.2) |
| Missing | 1 (0.8) | 1 (100) | 0 (0) | 0 (0) |
| Chemsex users, N (%) | | | | |
| Chemsex no | 120 (91.6) | 96 (80) | 14 (11.7) | 10 (8.3) |
| Chemsex yes | 10 (7.6) | 10 (100) | 0 (0) | 0 (0) |
| Prefer not to answer | 1 (0.8) | 0 (0) | 1 (100) | 0 (0) |
| Perception of risk to get MPX, N (%) | | | | |
| Not worried | 26 (19.8) | 14 (53.8) | 5 (19.2) | 7 (26.9) |
| Slightly worried | 40 (30.5) | 33 (82.5) | 5 (12.5) | 2 (5) |
| Moderately worried | 26 (19.8) | 23 (88.5) | 3 (11.5) | 0 (0) |
| Worried | 23 (17.6) | 21 (91.3) | 2 (8.7) | 0 (0) |
| Very worried | 15 (11.5) | 14 (93.3) | 0 (0) | 1 (6.7) |
| I don't know | 1 (0.8) | 1 (100) | 0 (0) | 0 (0) |
| Perception of MPX severity, N (%) | | | | |
| Not severe | 5 (3.8) | 2 (40) | 1 (20) | 2 (40) |
| Slightly severe | 13 (9.9) | 12 (92.3) | 0 (0) | 1 (7.7) |
| Moderately severe | 48 (36.6) | 40 (83.3) | 5 (10.4) | 3 (6.2) |
| Severe | 37 (28.2) | 33 (89.2) | 3 (8.1) | 1 (2.7) |
| Very severe | 13 (9.9) | 9 (69.2) | 3 (23.1) | 1 (7.7) |
| I don't know | 14 (10.7) | 9 (64.3) | 3 (21.4) | 2 (14.3) |
| Missing | 1 (0.8) | 1 (100) | 0 (0) | 0 (0) |
| Know someone or diagnosed with MPX, N (%) | | | | |
| No | 111 (84.7) | 88 (79.3) | 13 (11.7) | 10 (9) |
| Yes, only me | 1 (0.8) | 1 (100) | 0 (0) | 0 (0) |
| Yes, me and someone I know | 3 (2.3) | 3 (100) | 0 (0) | 0 (0) |
| Yes, only someone I know | 10 (7.6) | 9 (90) | 1 (10) | 0 (0) |
| I don't know | 6 (4.6) | 5 (83.3) | 1 (16.7) | 0 (0) |

Description of the sample for the Baltics subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal |
|--|--------------------|------------|-----------|----------|
| Perception of vaccine protection in general, N (%) | | | | |
| Strongly disagree | 10 (7.6) | 10 (100) | 0 (0) | 0 (0) |
| Slightly disagree | 6 (4.6) | 2 (33.3) | 2 (33.3) | 2 (33.3) |
| Neither disagree nor agree | 3 (2.3) | 2 (66.7) | 1 (33.3) | 0 (0) |
| Slightly agree | 19 (14.5) | 12 (63.2) | 4 (21.1) | 3 (15.8) |
| Strongly agree | 92 (70.2) | 80 (87) | 7 (7.6) | 5 (5.4) |
| I don't know | 1 (0.8) | 0 (0) | 1 (100) | 0 (0) |
| Worried about being treated differently due to MPX, N (%) | | | | |
| No | 41 (31.3) | 29 (70.7) | 10 (24.4) | 2 (4.9) |
| Yes | 58 (44.3) | 52 (89.7) | 2 (3.4) | 4 (6.9) |
| I don't know | 30 (22.9) | 24 (80) | 2 (6.7) | 4 (13.3) |
| Missing | 2 (1.5) | 1 (50) | 1 (50) | 0 (0) |

Eastern Europe

Description of the sample for the Eastern Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|----------------|-------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 1602 (100) | 1060 (66.2) | 274 (17.1) | 249 (15.5) | 19 (1.2) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 66 (4.6) | 51 (77.3) | 12 (18.2) | 3 (4.5) | 0 (0) |
| With my general practitioner | 181 (12.6) | 117 (64.6) | 46 (25.4) | 15 (8.3) | 3 (1.7) |
| In a community-based centre | 98 (6.8) | 78 (79.6) | 14 (14.3) | 6 (6.1) | 0 (0) |
| In a vaccination program centre | 356 (24.7) | 264 (74.2) | 70 (19.7) | 19 (5.3) | 3 (0.8) |
| It doesn't matter | 667 (46.3) | 524 (78.6) | 109 (16.3) | 32 (4.8) | 2 (0.3) |
| I don't know | 62 (4.3) | 20 (32.3) | 22 (35.5) | 12 (19.4) | 8 (12.9) |
| Missing | 10 (0.7) | 6 (60) | 1 (10) | 0 (0) | 3 (30) |
| Age, Median (IQR) | 31.0 (24 - 38) | 31.0 (24 - 37) | 31.0 (24 - 38) | 34.0 (26 - 40) | 33.0 (28.5 - 39) |
| Age category, N (%) | | | | | |
| 18-29 | 695 (43.4) | 473 (68.1) | 120 (17.3) | 96 (13.8) | 6 (0.9) |
| 30-39 | 589 (36.8) | 387 (65.7) | 105 (17.8) | 89 (15.1) | 8 (1.4) |
| 40-49 | 255 (15.9) | 167 (65.5) | 35 (13.7) | 49 (19.2) | 4 (1.6) |
| 50-84 | 63 (3.9) | 33 (52.4) | 14 (22.2) | 15 (23.8) | 1 (1.6) |
| Region of residence, N (%) | | | | | |
| Eastern Europe | 1602 (100) | 1060 (66.2) | 274 (17.1) | 249 (15.5) | 19 (1.2) |
| Migrants, N (%) | | | | | |
| No | 1422 (88.8) | 940 (66.1) | 243 (17.1) | 225 (15.8) | 14 (1) |
| Yes | 180 (11.2) | 120 (66.7) | 31 (17.2) | 24 (13.3) | 5 (2.8) |
| Migrant Origin, N (%) | | | | | |
| Baltics | 2 (1.1) | 1 (50) | 1 (50) | 0 (0) | 0 (0) |
| Caribbean | 2 (1.1) | 1 (50) | 0 (0) | 0 (0) | 1 (50) |
| Central Europe | 30 (16.7) | 19 (63.3) | 7 (23.3) | 3 (10) | 1 (3.3) |

Description of the sample for the Eastern Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|---|--------------------|------------|------------|------------|-------------------|
| Eastern Europe | 119 (66.1) | 83 (69.7) | 18 (15.1) | 15 (12.6) | 3 (2.5) |
| Eastern Mediterranean | 3 (1.7) | 2 (66.7) | 1 (33.3) | 0 (0) | 0 (0) |
| Mediterranean Europe | 3 (1.7) | 3 (100) | 0 (0) | 0 (0) | 0 (0) |
| Northern America | 2 (1.1) | 1 (50) | 1 (50) | 0 (0) | 0 (0) |
| South America | 1 (0.6) | 0 (0) | 0 (0) | 1 (100) | 0 (0) |
| South-East Asia | 3 (1.7) | 2 (66.7) | 1 (33.3) | 0 (0) | 0 (0) |
| South-East Europe | 3 (1.7) | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0) |
| Sub-Saharan Africa | 3 (1.7) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) |
| Western Europe | 7 (3.9) | 3 (42.9) | 1 (14.3) | 3 (42.9) | 0 (0) |
| Western Pacific | 2 (1.1) | 2 (100) | 0 (0) | 0 (0) | 0 (0) |
| HIV, N (%) | | | | | |
| HIV- | 1236 (77.2) | 818 (66.2) | 208 (16.8) | 198 (16) | 12 (1) |
| HIV+ on ART | 267 (16.7) | 182 (68.2) | 49 (18.4) | 33 (12.4) | 3 (1.1) |
| HIV+ not on ART | 15 (0.9) | 10 (66.7) | 0 (0) | 4 (26.7) | 1 (6.7) |
| HIV status unknown | 62 (3.9) | 37 (59.7) | 14 (22.6) | 10 (16.1) | 1 (1.6) |
| Prefer not to answer | 18 (1.1) | 11 (61.1) | 2 (11.1) | 4 (22.2) | 1 (5.6) |
| Missing | 4 (0.2) | 2 (50) | 1 (25) | 0 (0) | 1 (25) |
| PrEP, N (%) | | | | | |
| PrEP no | 1168 (88.5) | 757 (64.8) | 204 (17.5) | 196 (16.8) | 11 (0.9) |
| PrEP yes | 126 (9.5) | 97 (77) | 16 (12.7) | 12 (9.5) | 1 (0.8) |
| Missing | 26 (2) | 14 (53.8) | 5 (19.2) | 4 (15.4) | 3 (11.5) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 1380 (86.1) | 903 (65.4) | 242 (17.5) | 222 (16.1) | 13 (0.9) |
| STI yes | 152 (9.5) | 108 (71.1) | 23 (15.1) | 18 (11.8) | 3 (2) |
| STI unknown | 62 (3.9) | 44 (71) | 8 (12.9) | 9 (14.5) | 1 (1.6) |
| Prefer not to answer | 4 (0.2) | 2 (50) | 1 (25) | 0 (0) | 1 (25) |
| Missing | 4 (0.2) | 3 (75) | 0 (0) | 0 (0) | 1 (25) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 1481 (92.4) | 979 (66.1) | 262 (17.7) | 227 (15.3) | 13 (0.9) |
| Chemsex yes | 97 (6.1) | 62 (63.9) | 11 (11.3) | 21 (21.6) | 3 (3.1) |
| Prefer not to answer | 21 (1.3) | 17 (81) | 1 (4.8) | 1 (4.8) | 2 (9.5) |
| Missing | 3 (0.2) | 2 (66.7) | 0 (0) | 0 (0) | 1 (33.3) |
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 338 (21.1) | 137 (40.5) | 72 (21.3) | 127 (37.6) | 2 (0.6) |
| Slightly worried | 439 (27.4) | 301 (68.6) | 84 (19.1) | 51 (11.6) | 3 (0.7) |
| Moderately worried | 330 (20.6) | 245 (74.2) | 55 (16.7) | 30 (9.1) | 0 (0) |
| Worried | 317 (19.8) | 254 (80.1) | 39 (12.3) | 23 (7.3) | 1 (0.3) |
| Very worried | 124 (7.7) | 102 (82.3) | 12 (9.7) | 8 (6.5) | 2 (1.6) |
| I don't know | 53 (3.3) | 21 (39.6) | 12 (22.6) | 10 (18.9) | 10 (18.9) |
| Missing | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 1 (100) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 63 (3.9) | 18 (28.6) | 5 (7.9) | 40 (63.5) | 0 (0) |
| Slightly severe | 141 (8.8) | 69 (48.9) | 29 (20.6) | 41 (29.1) | 2 (1.4) |
| Moderately severe | 489 (30.5) | 316 (64.6) | 97 (19.8) | 74 (15.1) | 2 (0.4) |
| Severe | 433 (27) | 332 (76.7) | 59 (13.6) | 40 (9.2) | 2 (0.5) |
| Very severe | 205 (12.8) | 168 (82) | 21 (10.2) | 11 (5.4) | 5 (2.4) |
| I don't know | 269 (16.8) | 157 (58.4) | 62 (23) | 43 (16) | 7 (2.6) |
| Missing | 2 (0.1) | 0 (0) | 1 (50) | 0 (0) | 1 (50) |

Description of the sample for the Eastern Europe subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|------------|------------|------------|-------------------|
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 1455 (90.8) | 962 (66.1) | 252 (17.3) | 230 (15.8) | 11 (0.8) |
| Yes, only me | 1 (0.1) | 1 (100) | 0 (0) | 0 (0) | 0 (0) |
| Yes, me and someone I know | 4 (0.2) | 3 (75) | 0 (0) | 1 (25) | 0 (0) |
| Yes, only someone I know | 17 (1.1) | 16 (94.1) | 1 (5.9) | 0 (0) | 0 (0) |
| I don't know | 119 (7.4) | 78 (65.5) | 21 (17.6) | 17 (14.3) | 3 (2.5) |
| Prefer not to answer | 4 (0.2) | 0 (0) | 0 (0) | 0 (0) | 4 (100) |
| Missing | 2 (0.1) | 0 (0) | 0 (0) | 1 (50) | 1 (50) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 56 (3.5) | 18 (32.1) | 4 (7.1) | 32 (57.1) | 2 (3.6) |
| Slightly disagree | 118 (7.4) | 36 (30.5) | 38 (32.2) | 43 (36.4) | 1 (0.8) |
| Neither disagree nor agree | 54 (3.4) | 9 (16.7) | 13 (24.1) | 31 (57.4) | 1 (1.9) |
| Slightly agree | 289 (18) | 144 (49.8) | 79 (27.3) | 64 (22.1) | 2 (0.7) |
| Strongly agree | 1018 (63.5) | 831 (81.6) | 121 (11.9) | 59 (5.8) | 7 (0.7) |
| I don't know | 65 (4.1) | 21 (32.3) | 19 (29.2) | 20 (30.8) | 5 (7.7) |
| Missing | 2 (0.1) | 1 (50) | 0 (0) | 0 (0) | 1 (50) |
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 754 (47.1) | 448 (59.4) | 131 (17.4) | 169 (22.4) | 6 (0.8) |
| Yes | 361 (22.5) | 273 (75.6) | 53 (14.7) | 35 (9.7) | 0 (0) |
| I don't know | 461 (28.8) | 330 (71.6) | 85 (18.4) | 42 (9.1) | 4 (0.9) |
| Prefer not to answer | 22 (1.4) | 8 (36.4) | 4 (18.2) | 3 (13.6) | 7 (31.8) |
| Missing | 4 (0.2) | 1 (25) | 1 (25) | 0 (0) | 2 (50) |

Mediterranean Europe

Description of the sample for the Mediterranean Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|-------------------|----------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 11424 (100) | 9826 (86) | 856 (7.5) | 686 (6) | 56 (0.5) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 1241 (11.3) | 1129 (91) | 83 (6.7) | 24 (1.9) | 5 (0.4) |
| With my general practitioner | 1811 (16.4) | 1551 (85.6) | 189 (10.4) | 63 (3.5) | 8 (0.4) |
| In a community-based centre | 436 (4) | 382 (87.6) | 49 (11.2) | 5 (1.1) | 0 (0) |
| In a vaccination program centre | 2262 (20.5) | 1989 (87.9) | 206 (9.1) | 58 (2.6) | 9 (0.4) |
| It doesn't matter | 5057 (45.8) | 4673 (92.4) | 278 (5.5) | 100 (2) | 6 (0.1) |
| I don't know | 186 (1.7) | 82 (44.1) | 48 (25.8) | 38 (20.4) | 18 (9.7) |
| Missing | 38 (0.3) | 20 (52.6) | 3 (7.9) | 5 (13.2) | 10 (26.3) |
| Age, Median (IQR) | 39.0 (31 - 47) | 39.0 (31 - 47) | 38.0 (29 - 48) | 39.0 (30 - 49.75) | 35.5 (28.75 - 43.25) |

Description of the sample for the Mediterranean Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|---|--------------------|-------------|-----------|-----------|-------------------|
| Age category, N (%) | | | | | |
| 18-29 | 2462 (21.6) | 2070 (84.1) | 221 (9) | 154 (6.3) | 17 (0.7) |
| 30-39 | 3570 (31.2) | 3097 (86.8) | 248 (6.9) | 204 (5.7) | 21 (0.6) |
| 40-49 | 3103 (27.2) | 2735 (88.1) | 204 (6.6) | 156 (5) | 8 (0.3) |
| 50-84 | 2289 (20) | 1924 (84.1) | 183 (8) | 172 (7.5) | 10 (0.4) |
| Region of residence, N (%) | | | | | |
| Mediterranean Europe | 11424 (100) | 9826 (86) | 856 (7.5) | 686 (6) | 56 (0.5) |
| Migrants, N (%) | | | | | |
| No | 9505 (83.2) | 8118 (85.4) | 754 (7.9) | 588 (6.2) | 45 (0.5) |
| Yes | 1919 (16.8) | 1708 (89) | 102 (5.3) | 98 (5.1) | 11 (0.6) |
| Migrant Origin, N (%) | | | | | |
| Baltics | 4 (0.2) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| Caribbean | 51 (2.7) | 45 (88.2) | 3 (5.9) | 2 (3.9) | 1 (2) |
| Central America | 92 (4.8) | 89 (96.7) | 0 (0) | 3 (3.3) | 0 (0) |
| Central Europe | 73 (3.8) | 53 (72.6) | 16 (21.9) | 4 (5.5) | 0 (0) |
| Eastern Europe | 27 (1.4) | 20 (74.1) | 3 (11.1) | 4 (14.8) | 0 (0) |
| Eastern Mediterranean | 39 (2) | 29 (74.4) | 4 (10.3) | 5 (12.8) | 1 (2.6) |
| Europe | 176 (9.2) | 150 (85.2) | 11 (6.2) | 14 (8) | 1 (0.6) |
| Northern America | 50 (2.6) | 43 (86) | 3 (6) | 4 (8) | 0 (0) |
| Northern Europe | 13 (0.7) | 11 (84.6) | 1 (7.7) | 1 (7.7) | 0 (0) |
| South America | 972 (50.7) | 908 (93.4) | 39 (4) | 22 (2.3) | 3 (0.3) |
| South-East Asia | 7 (0.4) | 6 (85.7) | 0 (0) | 0 (0) | 1 (14.3) |
| South-East Europe | 38 (2) | 28 (73.7) | 1 (2.6) | 8 (21.1) | 1 (2.6) |
| Sub-Saharan Africa | 67 (3.5) | 55 (82.1) | 5 (7.5) | 5 (7.5) | 2 (3) |
| Western Europe | 288 (15) | 246 (85.4) | 15 (5.2) | 26 (9) | 1 (0.3) |
| Western Pacific | 22 (1.1) | 21 (95.5) | 1 (4.5) | 0 (0) | 0 (0) |
| HIV, N (%) | | | | | |
| HIV- | 9438 (82.6) | 8075 (85.6) | 738 (7.8) | 583 (6.2) | 42 (0.4) |
| HIV+ on ART | 1404 (12.3) | 1293 (92.1) | 54 (3.8) | 54 (3.8) | 3 (0.2) |
| HIV+ not on ART | 27 (0.2) | 25 (92.6) | 0 (0) | 2 (7.4) | 0 (0) |
| HIV status | | | | | |
| unknown | 388 (3.4) | 304 (78.4) | 52 (13.4) | 30 (7.7) | 2 (0.5) |
| Prefer not to answer | 131 (1.1) | 101 (77.1) | 8 (6.1) | 14 (10.7) | 8 (6.1) |
| Missing | 36 (0.3) | 28 (77.8) | 4 (11.1) | 3 (8.3) | 1 (2.8) |
| PrEP, N (%) | | | | | |
| PrEP no | 7918 (79.2) | 6595 (83.3) | 714 (9) | 568 (7.2) | 41 (0.5) |
| PrEP yes | 1973 (19.7) | 1834 (93) | 75 (3.8) | 54 (2.7) | 10 (0.5) |
| Missing | 102 (1) | 79 (77.5) | 13 (12.7) | 8 (7.8) | 2 (2) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 9038 (79.1) | 7663 (84.8) | 715 (7.9) | 616 (6.8) | 44 (0.5) |
| STI yes | 2179 (19.1) | 2001 (91.8) | 115 (5.3) | 56 (2.6) | 7 (0.3) |
| STI unknown | 149 (1.3) | 120 (80.5) | 20 (13.4) | 8 (5.4) | 1 (0.7) |
| Prefer not to answer | 49 (0.4) | 36 (73.5) | 6 (12.2) | 5 (10.2) | 2 (4.1) |
| Missing | 9 (0.1) | 6 (66.7) | 0 (0) | 1 (11.1) | 2 (22.2) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 10464 (91.6) | 8957 (85.6) | 822 (7.9) | 637 (6.1) | 48 (0.5) |
| Chemsex yes | 871 (7.6) | 798 (91.6) | 32 (3.7) | 38 (4.4) | 3 (0.3) |
| Prefer not to answer | 68 (0.6) | 54 (79.4) | 2 (2.9) | 10 (14.7) | 2 (2.9) |
| Missing | 21 (0.2) | 17 (81) | 0 (0) | 1 (4.8) | 3 (14.3) |

Description of the sample for the Mediterranean Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|------------|------------|-------------------|
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 1173 (10.3) | 628 (53.5) | 153 (13) | 385 (32.8) | 7 (0.6) |
| Slightly worried | 2627 (23) | 2156 (82.1) | 302 (11.5) | 158 (6) | 11 (0.4) |
| Moderately worried | 2336 (20.4) | 2099 (89.9) | 170 (7.3) | 58 (2.5) | 9 (0.4) |
| Worried | 2817 (24.7) | 2615 (92.8) | 141 (5) | 52 (1.8) | 9 (0.3) |
| Very worried | 2303 (20.2) | 2225 (96.6) | 57 (2.5) | 18 (0.8) | 3 (0.1) |
| I don't know | 158 (1.4) | 98 (62) | 33 (20.9) | 15 (9.5) | 12 (7.6) |
| Missing | 10 (0.1) | 5 (50) | 0 (0) | 0 (0) | 5 (50) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 550 (4.8) | 302 (54.9) | 43 (7.8) | 201 (36.5) | 4 (0.7) |
| Slightly severe | 1582 (13.8) | 1287 (81.4) | 149 (9.4) | 140 (8.8) | 6 (0.4) |
| Moderately severe | 3567 (31.2) | 3163 (88.7) | 263 (7.4) | 135 (3.8) | 6 (0.2) |
| Severe | 3171 (27.8) | 2905 (91.6) | 182 (5.7) | 76 (2.4) | 8 (0.3) |
| Very severe | 1600 (14) | 1515 (94.7) | 54 (3.4) | 24 (1.5) | 7 (0.4) |
| I don't know | 947 (8.3) | 651 (68.7) | 165 (17.4) | 110 (11.6) | 21 (2.2) |
| Missing | 7 (0.1) | 3 (42.9) | 0 (0) | 0 (0) | 4 (57.1) |
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 9094 (79.6) | 7691 (84.6) | 746 (8.2) | 619 (6.8) | 38 (0.4) |
| Yes, only me | 89 (0.8) | 81 (91) | 4 (4.5) | 3 (3.4) | 1 (1.1) |
| Yes, me and someone I know | 322 (2.8) | 295 (91.6) | 14 (4.3) | 12 (3.7) | 1 (0.3) |
| Yes, only someone I know | 1051 (9.2) | 991 (94.3) | 35 (3.3) | 23 (2.2) | 2 (0.2) |
| I don't know | 804 (7) | 716 (89.1) | 55 (6.8) | 26 (3.2) | 7 (0.9) |
| Prefer not to answer | 49 (0.4) | 43 (87.8) | 1 (2) | 3 (6.1) | 2 (4.1) |
| Missing | 15 (0.1) | 9 (60) | 1 (6.7) | 0 (0) | 5 (33.3) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 368 (3.2) | 294 (79.9) | 23 (6.2) | 50 (13.6) | 1 (0.3) |
| Slightly disagree | 161 (1.4) | 77 (47.8) | 28 (17.4) | 54 (33.5) | 2 (1.2) |
| Neither disagree nor agree | 212 (1.9) | 72 (34) | 57 (26.9) | 76 (35.8) | 7 (3.3) |
| Slightly agree | 2773 (24.3) | 2181 (78.7) | 298 (10.7) | 279 (10.1) | 15 (0.5) |
| Strongly agree | 7779 (68.1) | 7135 (91.7) | 420 (5.4) | 204 (2.6) | 20 (0.3) |
| I don't know | 128 (1.1) | 65 (50.8) | 30 (23.4) | 22 (17.2) | 11 (8.6) |
| Missing | 3 (0) | 2 (66.7) | 0 (0) | 1 (33.3) | 0 (0) |
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 4104 (35.9) | 3315 (80.8) | 343 (8.4) | 424 (10.3) | 22 (0.5) |
| Yes | 3346 (29.3) | 3038 (90.8) | 197 (5.9) | 104 (3.1) | 7 (0.2) |
| I don't know | 1323 (11.6) | 1137 (85.9) | 120 (9.1) | 61 (4.6) | 5 (0.4) |
| Prefer not to answer | 86 (0.8) | 52 (60.5) | 15 (17.4) | 8 (9.3) | 11 (12.8) |
| Missing | 2565 (22.5) | 2284 (89) | 181 (7.1) | 89 (3.5) | 11 (0.4) |

Northern Europe

Description of the sample for the Northern Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|----------------|-------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 3126 (100) | 2725 (87.2) | 223 (7.1) | 164 (5.2) | 14 (0.4) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 429 (14) | 400 (93.2) | 22 (5.1) | 7 (1.6) | 0 (0) |
| With my general practitioner | 322 (10.5) | 265 (82.3) | 49 (15.2) | 8 (2.5) | 0 (0) |
| In a community-based centre | 98 (3.2) | 88 (89.8) | 9 (9.2) | 1 (1) | 0 (0) |
| In a vaccination program centre | 428 (14) | 369 (86.2) | 39 (9.1) | 20 (4.7) | 0 (0) |
| It doesn't matter | 1703 (55.6) | 1572 (92.3) | 78 (4.6) | 51 (3) | 2 (0.1) |
| I don't know | 67 (2.2) | 25 (37.3) | 24 (35.8) | 12 (17.9) | 6 (9) |
| Missing | 14 (0.5) | 6 (42.9) | 2 (14.3) | 0 (0) | 6 (42.9) |
| Age, Median (IQR) | 40.0 (31 - 50) | 41.0 (31 - 51) | 38.0 (29 - 48) | 37.5 (29 - 46) | 36.0 (24 - 45.25) |
| Age category, N (%) | | | | | |
| 18-29 | 672 (21.5) | 559 (83.2) | 64 (9.5) | 43 (6.4) | 6 (0.9) |
| 30-39 | 813 (26) | 706 (86.8) | 56 (6.9) | 50 (6.2) | 1 (0.1) |
| 40-49 | 810 (25.9) | 713 (88) | 53 (6.5) | 38 (4.7) | 6 (0.7) |
| 50-84 | 831 (26.6) | 747 (89.9) | 50 (6) | 33 (4) | 1 (0.1) |
| Region of residence, N (%) | | | | | |
| Northern Europe | 3126 (100) | 2725 (87.2) | 223 (7.1) | 164 (5.2) | 14 (0.4) |
| Migrants, N (%) | | | | | |
| No | 2522 (80.7) | 2197 (87.1) | 182 (7.2) | 136 (5.4) | 7 (0.3) |
| Yes | 604 (19.3) | 528 (87.4) | 41 (6.8) | 28 (4.6) | 7 (1.2) |
| Migrant Origin, N (%) | | | | | |
| Baltics | 15 (2.5) | 12 (80) | 2 (13.3) | 1 (6.7) | 0 (0) |
| Caribbean | 4 (0.7) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| Central America | 10 (1.7) | 9 (90) | 1 (10) | 0 (0) | 0 (0) |
| Central Europe | 50 (8.3) | 43 (86) | 6 (12) | 0 (0) | 1 (2) |
| Eastern Europe | 18 (3) | 17 (94.4) | 1 (5.6) | 0 (0) | 0 (0) |
| Eastern Europe | 42 (7) | 34 (81) | 3 (7.1) | 2 (4.8) | 3 (7.1) |
| Mediterranean Europe | 70 (11.6) | 62 (88.6) | 2 (2.9) | 5 (7.1) | 1 (1.4) |
| Northern America | 44 (7.3) | 41 (93.2) | 0 (0) | 3 (6.8) | 0 (0) |
| Northern Europe | 78 (12.9) | 69 (88.5) | 7 (9) | 2 (2.6) | 0 (0) |
| South America | 58 (9.6) | 54 (93.1) | 2 (3.4) | 1 (1.7) | 1 (1.7) |
| South-East Asia | 20 (3.3) | 14 (70) | 4 (20) | 2 (10) | 0 (0) |
| South-East Europe | 43 (7.1) | 36 (83.7) | 6 (14) | 1 (2.3) | 0 (0) |
| Sub-Saharan Africa | 10 (1.7) | 7 (70) | 1 (10) | 2 (20) | 0 (0) |
| Western Europe | 97 (16.1) | 85 (87.6) | 4 (4.1) | 7 (7.2) | 1 (1) |
| Western Pacific | 45 (7.5) | 41 (91.1) | 2 (4.4) | 2 (4.4) | 0 (0) |
| HIV, N (%) | | | | | |
| HIV- | 2787 (89.2) | 2418 (86.8) | 204 (7.3) | 153 (5.5) | 12 (0.4) |
| HIV+ on ART | 252 (8.1) | 238 (94.4) | 9 (3.6) | 5 (2) | 0 (0) |
| HIV+ not on ART | 10 (0.3) | 6 (60) | 2 (20) | 2 (20) | 0 (0) |
| HIV status unknown | 49 (1.6) | 39 (79.6) | 6 (12.2) | 3 (6.1) | 1 (2) |
| Prefer not to answer | 20 (0.6) | 17 (85) | 2 (10) | 1 (5) | 0 (0) |
| Missing | 8 (0.3) | 7 (87.5) | 0 (0) | 0 (0) | 1 (12.5) |
| PrEP, N (%) | | | | | |
| PrEP no | 2084 (72.8) | 1734 (83.2) | 198 (9.5) | 141 (6.8) | 11 (0.5) |
| PrEP yes | 751 (26.2) | 725 (96.5) | 12 (1.6) | 13 (1.7) | 1 (0.1) |

Description of the sample for the Northern Europe subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|---|--------------------|-------------|------------|------------|-------------------|
| Missing | 29 (1) | 22 (75.9) | 2 (6.9) | 3 (10.3) | 2 (6.9) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 2506 (80.2) | 2149 (85.8) | 202 (8.1) | 144 (5.7) | 11 (0.4) |
| STI yes | 577 (18.5) | 544 (94.3) | 14 (2.4) | 18 (3.1) | 1 (0.2) |
| STI unknown | 33 (1.1) | 24 (72.7) | 7 (21.2) | 2 (6.1) | 0 (0) |
| Prefer not to answer | 3 (0.1) | 3 (100) | 0 (0) | 0 (0) | 0 (0) |
| Missing | 7 (0.2) | 5 (71.4) | 0 (0) | 0 (0) | 2 (28.6) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 2927 (93.6) | 2550 (87.1) | 214 (7.3) | 151 (5.2) | 12 (0.4) |
| Chemsex yes | 167 (5.3) | 148 (88.6) | 7 (4.2) | 12 (7.2) | 0 (0) |
| Prefer not to answer | 25 (0.8) | 22 (88) | 2 (8) | 1 (4) | 0 (0) |
| Missing | 7 (0.2) | 5 (71.4) | 0 (0) | 0 (0) | 2 (28.6) |
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 643 (20.6) | 415 (64.5) | 102 (15.9) | 124 (19.3) | 2 (0.3) |
| Slightly worried | 927 (29.7) | 838 (90.4) | 63 (6.8) | 25 (2.7) | 1 (0.1) |
| Moderately worried | 665 (21.3) | 625 (94) | 33 (5) | 7 (1.1) | 0 (0) |
| Worried | 524 (16.8) | 505 (96.4) | 15 (2.9) | 2 (0.4) | 2 (0.4) |
| Very worried | 315 (10.1) | 307 (97.5) | 3 (1) | 5 (1.6) | 0 (0) |
| I don't know | 45 (1.4) | 33 (73.3) | 7 (15.6) | 1 (2.2) | 4 (8.9) |
| Missing | 7 (0.2) | 2 (28.6) | 0 (0) | 0 (0) | 5 (71.4) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 106 (3.4) | 58 (54.7) | 7 (6.6) | 41 (38.7) | 0 (0) |
| Slightly severe | 447 (14.3) | 357 (79.9) | 48 (10.7) | 41 (9.2) | 1 (0.2) |
| Moderately severe | 1014 (32.4) | 904 (89.2) | 75 (7.4) | 35 (3.5) | 0 (0) |
| Severe | 1011 (32.3) | 929 (91.9) | 51 (5) | 27 (2.7) | 4 (0.4) |
| Very severe | 391 (12.5) | 376 (96.2) | 7 (1.8) | 7 (1.8) | 1 (0.3) |
| I don't know | 150 (4.8) | 98 (65.3) | 35 (23.3) | 13 (8.7) | 4 (2.7) |
| Missing | 7 (0.2) | 3 (42.9) | 0 (0) | 0 (0) | 4 (57.1) |
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 2517 (80.5) | 2161 (85.9) | 203 (8.1) | 146 (5.8) | 7 (0.3) |
| Yes, only me | 9 (0.3) | 7 (77.8) | 0 (0) | 2 (22.2) | 0 (0) |
| Yes, me and someone I know | 31 (1) | 28 (90.3) | 0 (0) | 3 (9.7) | 0 (0) |
| Yes, only someone I know | 371 (11.9) | 361 (97.3) | 5 (1.3) | 4 (1.1) | 1 (0.3) |
| I know | 188 (6) | 164 (87.2) | 15 (8) | 8 (4.3) | 1 (0.5) |
| I don't know | 188 (6) | 164 (87.2) | 15 (8) | 8 (4.3) | 1 (0.5) |
| Prefer not to answer | 5 (0.2) | 4 (80) | 0 (0) | 0 (0) | 1 (20) |
| Missing | 5 (0.2) | 0 (0) | 0 (0) | 1 (20) | 4 (80) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 93 (3) | 78 (83.9) | 6 (6.5) | 9 (9.7) | 0 (0) |
| Slightly disagree | 38 (1.2) | 19 (50) | 3 (7.9) | 15 (39.5) | 1 (2.6) |
| Neither disagree nor agree | 63 (2) | 23 (36.5) | 19 (30.2) | 18 (28.6) | 3 (4.8) |
| Slightly agree | 399 (12.8) | 282 (70.7) | 59 (14.8) | 55 (13.8) | 3 (0.8) |
| Strongly agree | 2506 (80.2) | 2307 (92.1) | 131 (5.2) | 65 (2.6) | 3 (0.1) |
| I don't know | 23 (0.7) | 15 (65.2) | 5 (21.7) | 2 (8.7) | 1 (4.3) |
| Missing | 4 (0.1) | 1 (25) | 0 (0) | 0 (0) | 3 (75) |

Description of the sample for the Northern Europe subregion. (*continued*)

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|-----------|-----------|-------------------|
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 1357 (43.4) | 1143 (84.2) | 107 (7.9) | 104 (7.7) | 3 (0.2) |
| Yes | 1209 (38.7) | 1118 (92.5) | 56 (4.6) | 34 (2.8) | 1 (0.1) |
| I don't know | 529 (16.9) | 443 (83.7) | 58 (11) | 25 (4.7) | 3 (0.6) |
| Prefer not to answer | 17 (0.5) | 12 (70.6) | 2 (11.8) | 1 (5.9) | 2 (11.8) |
| Missing | 14 (0.4) | 9 (64.3) | 0 (0) | 0 (0) | 5 (35.7) |

Western Europe

Description of the sample for the Western Europe subregion.

| Question | Sample Description | MPX Vaccine acceptance | | | |
|---|--------------------|------------------------|----------------|----------------|-------------------|
| | | Acceptance | Hesitancy | Refusal | No answer/Missing |
| Total, N (%) | 12090 (100) | 10219 (84.5) | 847 (7) | 803 (6.6) | 221 (1.8) |
| Preferred place to get vaccinated, N (%) | | | | | |
| In an STI clinic | 1258 (11.5) | 1122 (89.2) | 93 (7.4) | 40 (3.2) | 3 (0.2) |
| With my general practitioner | 2256 (20.7) | 1950 (86.4) | 210 (9.3) | 91 (4) | 5 (0.2) |
| In a community-based centre | 260 (2.4) | 227 (87.3) | 28 (10.8) | 2 (0.8) | 3 (1.2) |
| In a vaccination program centre | 1569 (14.4) | 1363 (86.9) | 143 (9.1) | 60 (3.8) | 3 (0.2) |
| It doesn't matter | 5350 (49) | 4914 (91.9) | 286 (5.3) | 141 (2.6) | 9 (0.2) |
| I don't know | 177 (1.6) | 62 (35) | 52 (29.4) | 43 (24.3) | 20 (11.3) |
| Missing | 43 (0.4) | 16 (37.2) | 5 (11.6) | 3 (7) | 19 (44.2) |
| Age, Median (IQR) | 41.0 (32 - 50) | 42.0 (32 - 50) | 39.0 (30 - 49) | 39.0 (30 - 49) | 41.0 (32 - 52) |
| Age category, N (%) | | | | | |
| 18-29 | 2196 (18.2) | 1764 (80.3) | 209 (9.5) | 190 (8.7) | 33 (1.5) |
| 30-39 | 3244 (26.8) | 2734 (84.3) | 222 (6.8) | 217 (6.7) | 71 (2.2) |
| 40-49 | 3351 (27.7) | 2887 (86.2) | 209 (6.2) | 210 (6.3) | 45 (1.3) |
| 50-84 | 3299 (27.3) | 2834 (85.9) | 207 (6.3) | 186 (5.6) | 72 (2.2) |
| Region of residence, N (%) | | | | | |
| Western Europe | 12090 (100) | 10219 (84.5) | 847 (7) | 803 (6.6) | 221 (1.8) |
| Migrants, N (%) | | | | | |
| No | 9818 (81.2) | 8269 (84.2) | 712 (7.3) | 671 (6.8) | 166 (1.7) |
| Yes | 2272 (18.8) | 1950 (85.8) | 135 (5.9) | 132 (5.8) | 55 (2.4) |
| Migrant Origin, N (%) | | | | | |
| Baltics | 19 (0.8) | 16 (84.2) | 0 (0) | 2 (10.5) | 1 (5.3) |
| Caribbean | 28 (1.2) | 24 (85.7) | 2 (7.1) | 0 (0) | 2 (7.1) |
| Central America | 45 (2) | 41 (91.1) | 1 (2.2) | 2 (4.4) | 1 (2.2) |
| Central Europe | 181 (8) | 147 (81.2) | 11 (6.1) | 18 (9.9) | 5 (2.8) |
| Eastern Europe | 61 (2.7) | 45 (73.8) | 7 (11.5) | 8 (13.1) | 1 (1.6) |
| Eastern Mediterranean | 140 (6.2) | 121 (86.4) | 9 (6.4) | 9 (6.4) | 1 (0.7) |
| Mediterranean Europe | 439 (19.3) | 386 (87.9) | 28 (6.4) | 20 (4.6) | 5 (1.1) |
| Northern America | 104 (4.6) | 94 (90.4) | 4 (3.8) | 6 (5.8) | 0 (0) |

Description of the sample for the Western Europe subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|------------|------------|-------------------|
| Northern Europe | 33 (1.5) | 32 (97) | 0 (0) | 1 (3) | 0 (0) |
| South America | 199 (8.8) | 185 (93) | 8 (4) | 4 (2) | 2 (1) |
| South-East Asia | 33 (1.5) | 27 (81.8) | 3 (9.1) | 2 (6.1) | 1 (3) |
| South-East Europe | 144 (6.3) | 110 (76.4) | 18 (12.5) | 15 (10.4) | 1 (0.7) |
| Sub-Saharan Africa | 82 (3.6) | 69 (84.1) | 8 (9.8) | 4 (4.9) | 1 (1.2) |
| Western Europe | 592 (26.1) | 516 (87.2) | 31 (5.2) | 37 (6.2) | 8 (1.4) |
| Western Pacific | 77 (3.4) | 71 (92.2) | 3 (3.9) | 1 (1.3) | 2 (2.6) |
| Unclear Region | 95 (4.2) | 66 (69.5) | 2 (2.1) | 3 (3.2) | 24 (25.3) |
| HIV, N (%) | | | | | |
| HIV- | 10338 (85.5) | 8696 (84.1) | 742 (7.2) | 712 (6.9) | 188 (1.8) |
| HIV+ on ART | 1344 (11.1) | 1222 (90.9) | 45 (3.3) | 58 (4.3) | 19 (1.4) |
| HIV+ not on ART | 40 (0.3) | 31 (77.5) | 3 (7.5) | 6 (15) | 0 (0) |
| HIV status unknown | 243 (2) | 181 (74.5) | 39 (16) | 20 (8.2) | 3 (1.2) |
| Prefer not to answer | 102 (0.8) | 70 (68.6) | 17 (16.7) | 7 (6.9) | 8 (7.8) |
| Missing | 23 (0.2) | 19 (82.6) | 1 (4.3) | 0 (0) | 3 (13) |
| PrEP, N (%) | | | | | |
| PrEP no | 6826 (63.8) | 5458 (80) | 671 (9.8) | 617 (9) | 80 (1.2) |
| PrEP yes | 3818 (35.7) | 3466 (90.8) | 122 (3.2) | 118 (3.1) | 112 (2.9) |
| Missing | 62 (0.6) | 42 (67.7) | 6 (9.7) | 4 (6.5) | 10 (16.1) |
| STI in the last 12 months, N (%) | | | | | |
| STI no | 9205 (76.1) | 7645 (83.1) | 727 (7.9) | 709 (7.7) | 124 (1.3) |
| STI yes | 2706 (22.4) | 2441 (90.2) | 98 (3.6) | 84 (3.1) | 83 (3.1) |
| STI unknown | 134 (1.1) | 109 (81.3) | 16 (11.9) | 7 (5.2) | 2 (1.5) |
| Prefer not to answer | 29 (0.2) | 16 (55.2) | 5 (17.2) | 3 (10.3) | 5 (17.2) |
| Missing | 16 (0.1) | 8 (50) | 1 (6.2) | 0 (0) | 7 (43.8) |
| Chemsex users, N (%) | | | | | |
| Chemsex no | 10710 (88.6) | 9030 (84.3) | 799 (7.5) | 738 (6.9) | 143 (1.3) |
| Chemsex yes | 1301 (10.8) | 1136 (87.3) | 42 (3.2) | 62 (4.8) | 61 (4.7) |
| Prefer not to answer | 68 (0.6) | 50 (73.5) | 5 (7.4) | 3 (4.4) | 10 (14.7) |
| Missing | 11 (0.1) | 3 (27.3) | 1 (9.1) | 0 (0) | 7 (63.6) |
| Perception of risk to get MPX, N (%) | | | | | |
| Not worried | 1093 (9) | 544 (49.8) | 146 (13.4) | 387 (35.4) | 16 (1.5) |
| Slightly worried | 2024 (16.7) | 1529 (75.5) | 238 (11.8) | 216 (10.7) | 41 (2) |
| Moderately worried | 2976 (24.6) | 2555 (85.9) | 260 (8.7) | 116 (3.9) | 45 (1.5) |
| Worried | 3710 (30.7) | 3465 (93.4) | 121 (3.3) | 43 (1.2) | 81 (2.2) |
| Very worried | 2114 (17.5) | 2034 (96.2) | 43 (2) | 25 (1.2) | 12 (0.6) |
| I don't know | 157 (1.3) | 86 (54.8) | 38 (24.2) | 15 (9.6) | 18 (11.5) |
| Missing | 16 (0.1) | 6 (37.5) | 1 (6.2) | 1 (6.2) | 8 (50) |
| Perception of MPX severity, N (%) | | | | | |
| Not severe | 293 (2.4) | 92 (31.4) | 24 (8.2) | 172 (58.7) | 5 (1.7) |
| Slightly severe | 1110 (9.2) | 767 (69.1) | 126 (11.4) | 195 (17.6) | 22 (2) |
| Moderately severe | 3690 (30.5) | 3106 (84.2) | 333 (9) | 214 (5.8) | 37 (1) |
| Severe | 4628 (38.3) | 4181 (90.3) | 220 (4.8) | 115 (2.5) | 112 (2.4) |
| Very severe | 1858 (15.4) | 1768 (95.2) | 39 (2.1) | 32 (1.7) | 19 (1) |
| I don't know | 499 (4.1) | 303 (60.7) | 104 (20.8) | 74 (14.8) | 18 (3.6) |
| Missing | 12 (0.1) | 2 (16.7) | 1 (8.3) | 1 (8.3) | 8 (66.7) |
| Know someone or diagnosed with MPX, N (%) | | | | | |
| No | 8861 (73.3) | 7317 (82.6) | 721 (8.1) | 695 (7.8) | 128 (1.4) |
| Yes, only me | 112 (0.9) | 103 (92) | 1 (0.9) | 6 (5.4) | 2 (1.8) |

Description of the sample for the Western Europe subregion. *(continued)*

| Question | Sample Description | Acceptance | Hesitancy | Refusal | No answer/Missing |
|--|--------------------|-------------|------------|------------|-------------------|
| Yes, me and someone I know | 244 (2) | 220 (90.2) | 8 (3.3) | 11 (4.5) | 5 (2) |
| Yes, only someone I know | 2199 (18.2) | 2019 (91.8) | 62 (2.8) | 56 (2.5) | 62 (2.8) |
| I don't know | 649 (5.4) | 553 (85.2) | 52 (8) | 33 (5.1) | 11 (1.7) |
| Prefer not to answer | 14 (0.1) | 5 (35.7) | 2 (14.3) | 2 (14.3) | 5 (35.7) |
| Missing | 11 (0.1) | 2 (18.2) | 1 (9.1) | 0 (0) | 8 (72.7) |
| Perception of vaccine protection in general, N (%) | | | | | |
| Strongly disagree | 275 (2.4) | 197 (71.6) | 19 (6.9) | 57 (20.7) | 2 (0.7) |
| Slightly disagree | 142 (1.3) | 55 (38.7) | 24 (16.9) | 60 (42.3) | 3 (2.1) |
| Neither disagree nor agree | 351 (3.1) | 115 (32.8) | 71 (20.2) | 154 (43.9) | 11 (3.1) |
| Slightly agree | 2812 (24.9) | 2118 (75.3) | 391 (13.9) | 291 (10.3) | 12 (0.4) |
| Strongly agree | 7604 (67.4) | 7123 (93.7) | 291 (3.8) | 176 (2.3) | 14 (0.2) |
| I don't know | 93 (0.8) | 42 (45.2) | 21 (22.6) | 17 (18.3) | 13 (14) |
| Missing | 11 (0.1) | 4 (36.4) | 0 (0) | 0 (0) | 7 (63.6) |
| Worried about being treated differently due to MPX, N (%) | | | | | |
| No | 4226 (37.4) | 3408 (80.6) | 348 (8.2) | 453 (10.7) | 17 (0.4) |
| Yes | 4965 (44) | 4539 (91.4) | 259 (5.2) | 156 (3.1) | 11 (0.2) |
| I don't know | 1937 (17.2) | 1599 (82.6) | 203 (10.5) | 127 (6.6) | 8 (0.4) |
| Prefer not to answer | 68 (0.6) | 32 (47.1) | 6 (8.8) | 16 (23.5) | 14 (20.6) |
| Missing | 92 (0.8) | 76 (82.6) | 1 (1.1) | 3 (3.3) | 12 (13) |

S5. Model specification

We investigated MPX vaccine by modelling the rate of respondents declaring to “surely” or “probably” willing to get vaccinated as a binomial process through a Bayesian multilevel logistic regression model. We developed two kind of models.

A random intercept model was used to evaluate baseline vaccine acceptance levels:

$$Pr(V_i) \sim \text{Binom}(p_i, N_i)$$

$$\text{logit}(p_i) = \beta_0 + u_{R_i} + u_{R_i * C_i}$$

$$u_{R_i} \sim \text{Normal}(0, \sigma_R)$$

$$u_{R_i * C_i} \sim \text{Normal}(0, \sigma_{R * C})$$

$$\beta_0 \sim \text{StudentT}(3, 0, 2.5)$$

$$\sigma_R \sim \text{HalfNormal}(0, 1.5)$$

$$\sigma_{R * C} \sim \text{HalfNormal}(0, 0.5)$$

with V_i being the number of respondents being sure or probably willing to vaccinate over the total N_i , in the group i identified by a country C_i and the respective European subregion of residence R_i . The group average vaccine acceptance is defined by p_i .

The term u_{R_i} and $u_{R_i * C_i}$ represent the deviates over the general mean β_0 (i.e., the model intercept) respectively due to the subregion and the country inside the subregion of residence on the logit scale. These deviates are modelled as drawn by a normal distribution. The model priors are reported in the model formulation itself. The model was fitted with the R (R Core Team 2022) brms package (Bürkner 2017). The relative model formula is:

```
MPXWill | trials(N) ~ (1 | SubRegion/Country), family = binomial()
```

An expansion of this model with random slopes was used to assess the association of the investigated factors of interest with the vaccine acceptance rate. For each factor the following model was used:

$$Pr(V_{i,j}) \sim \text{Binom}(p_{i,j}, N_{i,j})$$

$$\text{logit}(p_{i,j}) = \beta_0 + u_{R_i} + u_{R_i * C_i} + X_j(\beta_j + \nu_{j,R_i} + \nu_{j,R_i * C_i})$$

$$\begin{bmatrix} u_R \\ \nu_{1,R} \\ \dots \\ \nu_{J,R} \end{bmatrix} \sim \text{MVNormal}\left(0, \mathbf{S}_R\right), \begin{bmatrix} u_{R * C} \\ \nu_{1,R * C} \\ \dots \\ \nu_{J,R * C} \end{bmatrix} \sim \text{MVNormal}\left(0, \mathbf{S}_{J,R * C}\right)$$

$$\mathbf{S}_R = \begin{pmatrix} \sigma_R & & & \\ & \sigma_{1,R} & & \\ & & \ddots & \\ & & & \sigma_{J,R} \end{pmatrix} \mathbf{R}_R \begin{pmatrix} \sigma_R & & & \\ & \sigma_{1,R} & & \\ & & \ddots & \\ & & & \sigma_{J,R} \end{pmatrix}$$

$$\mathbf{S}_{R * C} = \begin{pmatrix} \sigma_{R * C} & & & \\ & \sigma_{1,R * C} & & \\ & & \ddots & \\ & & & \sigma_{J,R * C} \end{pmatrix} \mathbf{R}_{R * C} \begin{pmatrix} \sigma_{R * C} & & & \\ & \sigma_{1,R * C} & & \\ & & \ddots & \\ & & & \sigma_{J,R * C} \end{pmatrix}$$

$$\beta_0 \sim \text{StudentT}(3, 0, 2.5)$$

$$\beta_{1 \dots J} \sim \text{StudentT}(3, 0, 1.5)$$

$$(\sigma_R, \sigma_{1 \dots J, R}) \sim \text{HalfNormal}(0, 1.5)$$

$$(\sigma_{R * C}, \sigma_{1 \dots J, R * C}) \sim \text{HalfNormal}(0, 0.5)$$

$$(\mathbf{R}_R, \mathbf{R}_{R * C}) \sim \text{LKJ}(2)$$

With β_j being the association parameter for the levels $j = 1 \dots J$ of the factor of interest X (e.g., age groups, MPX severity perception, etc...), excluding a reference level incorporated in the intercept. In addition to the deviates on the intercept (u_{R_i} and $u_{R_i * C_i}$) we have also the deviates on the association parameter ν_{j,R_i} and $\nu_{j,R_i * C_i}$. All the deviates at the same geographical level (SubRegion or Country inside SubRegion) are drawn from a multivariate normal distribution parameterised by the deviates marginal standard deviations σ and the correlation factor \mathbf{R} , which is give a restrictive LKJ(2) prior to reduce spurious correlation between the parameters. The relative model formula in the `brms` package is:

```
MPXWill | trials(N) ~ Pred + (Pred | SubRegion/Country), family = binomial()
```

with `Pred` being the factor of interest.

The models were fitted using 10,000 iterations on ten chains, with an adaptive delta of 0.99 (Carpenter et al. 2017). We checked model convergence through the \hat{R} statistic and the number of divergent iterations, adapting priors in order to have the first always below 1.01 and the seconds close to zero.

For the baseline model we reported the median and (5%, 95%) quantiles (Credible Intervals, CrI) of the posterior distribution of the average vaccine acceptance p_i . To predict p_i for a given subregion we compute $\text{logit}^{-1}(\beta_0 + u_{R_i})$, while for each country we compute $\text{logit}^{-1}(\beta_0 + u_{R_i} + u_{R_i * C_i})$, for each set of posterior values of the parameters.

For the association models we reported the posterior distribution of the geographically adjusted relative risk (aRR) of vaccine acceptance, described as above (median and CrI), for a given factor value j compared to a reference value. We extracted the aRR from the association model analytically for each set of posterior values of the parameters:

$$aRR_j = \frac{\text{logit}^{-1}(\beta_0 + \beta_j)}{\text{logit}^{-1}(\beta_0)}$$

We also report the aRR for each subregion i and :

$$aRR_{i,j} = \frac{\text{logit}^{-1}(\beta_0 + u_{R_i} + \beta_{i,j} + \nu_{j,R_i})}{\text{logit}^{-1}(\beta_0 + u_{R_i})}$$

The subregion specific aRR are reported in the Supplemental Material S7.

For comparison reasons, we also computed the fixed effect version of both models, that is, omitting the geographical random effects.

For the posterior distribution of the aRR we also report two inferential statistics:

1. probability of direction (pD) which is defined as $Pr(aRR > 1)$ if the median aRR is > 1 and viceversa if lower. This value defines the probability of an association given the data (and the priors). A pD $> 95\%$ represent a strong evidence of effect (Makowski, Ben-Shachar, and Lüdtke 2019).
2. probability of the region of practical equivalence (pROPE), defined as $Pr(0.95 < aRR < 1.05)$. It represent the probability of a trivial, non relevant effect and is a practical proxy of the null effect probability ($Pr(aRR = 1)$) but has more preferable properties (Makowski, Ben-Shachar, and Lüdtke 2019). A pROPE $> 50\%$ indicate compelling evidence in favor of a low relevancy of the association, while above 90% we can solidly report a factor as non-relevant.

The union of these two statistics allows to clearly define the existence and the importance of an association, e.g., a high pD with a very high pROPE indicate a defined association but with no practical implication. A both low pD and low pROPE indicate that the data doesn't allow to draw any definite conclusion. A low pD but high pROPE is a strong evidence in favor of the null hypothesis, that is, absence of association.

S6. Baseline MPX vaccine acceptance probabilities.

We report here the estimated posterior vaccine acceptance. The estimates refer to the non-geographically adjusted model, to the adjusted model considering only the global intercept, and to the estimates at the regional and country levels. We highlighted respectively in red or green the estimates whose 50% CrI is lower or higher than the same interval at the level of the adjusted global estimates.

Baseline MPX vaccine acceptance probability, global and by European subregion and country.

| Geographical Level | Location | Vaccine Acceptance | [90% CrI] | Sig. Diff. |
|--------------------|----------------------|--------------------|----------------|------------|
| Global | Global | 77.8% | [68%, 85%] | average |
| | Northern Europe | 87.8% | [84.8%, 90.4%] | higher |
| | Western Europe | 85.6% | [83.1%, 87.7%] | higher |
| | Mediterranean Europe | 84.7% | [81.4%, 87.3%] | higher |
| SubRegion | Baltics | 81.3% | [73.5%, 87.2%] | average |
| | Central Europe | 66.3% | [61.3%, 71%] | lower |
| | Eastern Europe | 65.7% | [59.9%, 71.1%] | lower |
| | South-East Europe | 65.7% | [60.9%, 70.2%] | lower |
| | Norway | 91.5% | [88.5%, 93.9%] | higher |
| | Portugal | 89.8% | [88.7%, 90.9%] | higher |
| | Denmark | 89.7% | [87.8%, 91.4%] | higher |
| Sweden | 88.6% | [87.2%, 90%] | higher | |
| United Kingdom | 88.6% | [85.5%, 91.2%] | higher | |
| Netherlands | 87.5% | [85.5%, 89.4%] | higher | |
| Ireland | 87.5% | [85.7%, 89.1%] | higher | |
| Spain | 87.4% | [86.5%, 88.1%] | higher | |
| Belgium | 87.3% | [85%, 89.3%] | higher | |
| Austria | 86.9% | [84.8%, 88.9%] | higher | |
| Luxembourg | 86.6% | [80.4%, 91.4%] | higher | |
| Iceland | 86.6% | [81.2%, 90.7%] | higher | |
| France | 86.3% | [85.5%, 87%] | higher | |
| Israel | 85.5% | [83.6%, 87.4%] | higher | |
| Germany | 85% | [83.9%, 86.1%] | higher | |
| Italy | 85% | [84%, 86%] | higher | |
| Monaco | 84.5% | [76.4%, 90%] | higher | |
| Andorra | 83.5% | [75.9%, 89.1%] | higher | |
| Finland | 83% | [80.8%, 85.1%] | higher | |
| Malta | 83% | [77.7%, 87.3%] | higher | |
| Latvia | 82.9% | [72.5%, 90%] | average | |

Baseline MPX vaccine acceptance probability, global and by European subregion and country.
(continued)

| Geographical Level | Location | Vaccine Acceptance | [90% CrI] | Sig. Diff. |
|--------------------|------------------------|--------------------|----------------|------------|
| Country | Estonia | 82.5% | [75.1%, 88.4%] | average |
| | Switzerland | 82.2% | [79.3%, 84.7%] | higher |
| | Liechtenstein | 80.2% | [70.1%, 86.8%] | average |
| | Lithuania | 79% | [71.3%, 85.3%] | average |
| | Croatia | 76% | [72.4%, 79.4%] | average |
| | Greece | 75.8% | [72.3%, 78.9%] | average |
| | Poland | 72.2% | [69.8%, 74.5%] | lower |
| | Romania | 71.9% | [68.4%, 75.2%] | lower |
| | Türkiye | 70% | [67.3%, 72.7%] | lower |
| | Russia | 68% | [65.8%, 70.1%] | lower |
| | Kyrgyzstan | 67.1% | [55.4%, 77.3%] | lower |
| | Montenegro | 67.1% | [56.5%, 76.4%] | lower |
| | Uzbekistan | 67% | [56%, 76.7%] | lower |
| | Slovenia | 67% | [55.4%, 77.1%] | lower |
| | Azerbaijan | 66.5% | [55.3%, 76.3%] | lower |
| | Georgia | 66.4% | [60.4%, 72.2%] | lower |
| | Armenia | 66.4% | [54.9%, 76.5%] | lower |
| | Kazakhstan | 65.9% | [58.5%, 72.5%] | lower |
| | Slovakia | 65.1% | [58.3%, 71.3%] | lower |
| | Hungary | 65% | [60.9%, 69.1%] | lower |
| | Ukraine | 64.7% | [61.1%, 68.2%] | lower |
| | Republic of Moldova | 64.6% | [52.8%, 75.2%] | lower |
| | Serbia | 64.5% | [60.6%, 68.2%] | lower |
| | Albania | 64.5% | [57.4%, 71.1%] | lower |
| | Tajikistan | 62.6% | [49.1%, 73.6%] | lower |
| | North Macedonia | 61.7% | [51.7%, 70.6%] | lower |
| | Cyprus | 61% | [51.7%, 69.4%] | lower |
| | Bosnia and Herzegovina | 60.2% | [49.8%, 69.5%] | lower |
| | Bulgaria | 60% | [54.6%, 65.1%] | lower |
| | Belarus | 57.8% | [50.3%, 64.9%] | lower |
| Czechia | 56.3% | [52%, 60.5%] | lower | |

Note:

Sig. Diff. represents a situation in which the 50% CrI is higher or lower than the global estimate 50% CrI.

S7. Factor association with MPX vaccine acceptance.

The following table report the estimated association of each factor investigated in the survey with the acceptance of the MPX vaccine. We report the location adjusted and unadjusted estimates.

Estimated factor association with MPX vaccine acceptance, unadjusted or adjusted by country of residence.

| Question | unadjusted | | | adjusted | | |
|-----------------------|-------------------|-------|-------|-------------------|-------|-------|
| | RR [90% CrI] | pD | pROPE | RR [90% CrI] | pD | pROPE |
| Age category | | | | | | |
| 30-39 | 1.06 [1.05, 1.07] | 100% | 14.4% | 1.04 [1.01, 1.08] | 97.2% | 71.4% |
| 40-49 | 1.09 [1.08, 1.11] | 100% | 0% | 1.06 [1.02, 1.11] | 99.3% | 35.7% |
| 50-84 | 1.1 [1.09, 1.12] | 100% | 0% | 1.05 [1, 1.11] | 94.2% | 43.2% |
| Migrants | | | | | | |
| Yes | 1.05 [1.04, 1.06] | 100% | 34.1% | 1.03 [1, 1.07] | 93.9% | 84.9% |
| Migrant Origin | | | | | | |
| Western Pacific | 1.13 [1.09, 1.17] | 100% | 0.2% | 1.18 [1.07, 1.32] | 99.1% | 2.6% |
| Central America | 1.15 [1.11, 1.18] | 100% | 0% | 1.16 [0.98, 1.3] | 94.1% | 6.8% |
| Caribbean | 1.11 [1.04, 1.16] | 99.3% | 7.3% | 1.15 [0.98, 1.32] | 93.4% | 10.2% |
| South America | 1.14 [1.12, 1.15] | 100% | 0% | 1.15 [1.07, 1.27] | 98.8% | 2.4% |
| Northern America | 1.09 [1.05, 1.13] | 99.9% | 5.3% | 1.11 [0.99, 1.25] | 94.2% | 16.2% |
| Baltics | 1.03 [0.92, 1.12] | 69.4% | 49.3% | 1.07 [0.82, 1.24] | 71.8% | 25.7% |
| Mediterranean Europe | 1.06 [1.04, 1.09] | 100% | 19.7% | 1.05 [0.95, 1.15] | 82.2% | 47.6% |
| Eastern Mediterranean | 1.04 [0.99, 1.08] | 90.1% | 69.6% | 1.04 [0.92, 1.18] | 74.1% | 44.6% |
| Northern Europe | 1.08 [1.01, 1.12] | 97.8% | 22.5% | 1.02 [0.65, 1.19] | 57.6% | 29.1% |
| Western Europe | 1.05 [1.03, 1.07] | 100% | 50.6% | 1.02 [0.94, 1.08] | 69.2% | 73.7% |
| South-East Asia | 0.98 [0.87, 1.06] | 65.2% | 58.6% | 0.99 [0.74, 1.2] | 54.4% | 30.8% |
| Sub-Saharan Africa | 1.02 [0.96, 1.08] | 73.5% | 75.9% | 0.98 [0.78, 1.15] | 59.5% | 40.4% |
| Eastern Europe | 0.89 [0.83, 0.94] | 100% | 1.8% | 0.97 [0.86, 1.09] | 66.2% | 53.6% |
| Central Europe | 0.93 [0.88, 0.97] | 100% | 16.3% | 0.94 [0.82, 1.04] | 85.3% | 40.1% |

Estimated factor association with MPX vaccine acceptance, unadjusted or adjusted by country of residence. (*continued*)

| Question | RR [90% CrI] | pD | pROPE | RR [90% CrI] | pD | pROPE |
|--------------------------------------|-------------------|-------|-------|-------------------|-------|-------|
| South-East Europe | 0.91 [0.86, 0.95] | 100% | 6.3% | 0.91 [0.79, 1.01] | 93.3% | 24.5% |
| HIV | | | | | | |
| HIV+ on ART | 1.08 [1.07, 1.09] | 100% | 0% | 1.1 [1.03, 1.17] | 98.2% | 8.1% |
| HIV+ not on ART | 0.92 [0.84, 0.99] | 97.3% | 23.3% | 0.96 [0.8, 1.1] | 68.5% | 43.2% |
| HIV status unknown | 0.88 [0.85, 0.91] | 100% | 0% | 0.9 [0.82, 0.96] | 99.2% | 7.6% |
| Prefer not to answer | 0.92 [0.87, 0.97] | 99.7% | 15.8% | 0.93 [0.83, 1.02] | 89.4% | 36.1% |
| Missing | 0.99 [0.89, 1.06] | 61.4% | 65.7% | 0.99 [0.71, 1.16] | 55.1% | 36% |
| PrEP | | | | | | |
| PrEP yes | 1.17 [1.16, 1.18] | 100% | 0% | 1.19 [1.12, 1.28] | 99.9% | 0.2% |
| Missing | 0.95 [0.89, 1.01] | 91.6% | 53.1% | 0.96 [0.83, 1.06] | 76.9% | 47.8% |
| STI in the last 12 months | | | | | | |
| STI yes | 1.12 [1.11, 1.13] | 100% | 0% | 1.14 [1.08, 1.21] | 100% | 0.4% |
| STI unknown | 0.94 [0.9, 0.98] | 99.7% | 34.8% | 0.96 [0.88, 1.03] | 82% | 60.1% |
| Prefer not to answer | 0.92 [0.82, 1] | 95.8% | 25% | 0.94 [0.75, 1.13] | 71.5% | 31.6% |
| Missing | 1 [0.91, 1.07] | 50.3% | 68.8% | 1.12 [0.98, 1.28] | 92.9% | 14.9% |
| Chemsex users | | | | | | |
| Chemsex yes | 1.08 [1.06, 1.09] | 100% | 0% | 1.1 [1.03, 1.18] | 98.9% | 9.5% |
| Prefer not to answer | 0.99 [0.94, 1.04] | 59.7% | 88.2% | 1.04 [0.93, 1.14] | 74.9% | 52.6% |
| Missing | 1.09 [0.97, 1.17] | 90.7% | 21.6% | 1.14 [0.91, 1.32] | 88.4% | 13.2% |
| Perception of risk to get MPX | | | | | | |
| Slightly worried | 1.58 [1.53, 1.62] | 100% | 0% | 1.69 [1.49, 1.96] | 100% | 0% |
| Moderately worried | 1.73 [1.69, 1.78] | 100% | 0% | 1.87 [1.6, 2.26] | 100% | 0% |
| Worried | 1.86 [1.82, 1.91] | 100% | 0% | 2.02 [1.69, 2.54] | 100% | 0% |
| Very worried | 1.91 [1.86, 1.96] | 100% | 0% | 2.06 [1.72, 2.61] | 100% | 0% |
| I don't know | 1.15 [1.08, 1.23] | 100% | 0.9% | 1.26 [1.11, 1.46] | 99.2% | 1.3% |
| Missing | 1.7 [1.37, 1.92] | 100% | 0.1% | 2.01 [1.5, 2.61] | 99.6% | 0.2% |

Estimated factor association with MPX vaccine acceptance, unadjusted or adjusted by country of residence. (*continued*)

| Question | RR [90% CrI] | pD | pROPE | RR [90% CrI] | pD | pROPE |
|--|-------------------|-------|-------|-------------------|-------|-------|
| Perception of MPX severity | | | | | | |
| Slightly severe | 1.75 [1.65, 1.85] | 100% | 0% | 2.03 [1.71, 2.44] | 100% | 0% |
| Moderately severe | 2.01 [1.9, 2.12] | 100% | 0% | 2.42 [1.93, 3.12] | 100% | 0% |
| Severe | 2.17 [2.05, 2.29] | 100% | 0% | 2.65 [2.05, 3.58] | 100% | 0% |
| Very severe | 2.25 [2.13, 2.38] | 100% | 0% | 2.78 [2.12, 3.81] | 100% | 0% |
| I don't know | 1.51 [1.42, 1.6] | 100% | 0% | 1.82 [1.51, 2.25] | 100% | 0% |
| Missing | 1.69 [1.19, 2.08] | 98.8% | 1% | 2.15 [1.24, 3.2] | 97.9% | 0.7% |
| Know someone or diagnosed with MPX | | | | | | |
| Yes, only me | 1.11 [1.06, 1.14] | 100% | 2.4% | 1.09 [0.91, 1.23] | 84.8% | 22.3% |
| Yes, me and someone I know | 1.13 [1.11, 1.15] | 100% | 0% | 1.14 [1.06, 1.26] | 99.4% | 2.7% |
| Yes, only someone I know | 1.16 [1.15, 1.17] | 100% | 0% | 1.2 [1.12, 1.31] | 100% | 0.1% |
| I don't know | 1.05 [1.03, 1.06] | 100% | 60.7% | 1.05 [1.01, 1.1] | 97.8% | 49.2% |
| Prefer not to answer | 1 [0.89, 1.08] | 53% | 60.5% | 0.8 [0.31, 1.12] | 82.9% | 13% |
| Missing | 0.9 [0.67, 1.07] | 80.7% | 25.4% | 0.73 [0.22, 1.1] | 87.1% | 10.8% |
| Perception of vaccine protection in general | | | | | | |
| Slightly disagree | 0.53 [0.48, 0.57] | 100% | 0% | 0.53 [0.42, 0.65] | 100% | 0% |
| Neither disagree nor agree | 0.41 [0.37, 0.44] | 100% | 0% | 0.36 [0.27, 0.47] | 100% | 0% |
| Slightly agree | 1.01 [0.98, 1.04] | 66.3% | 98.1% | 0.83 [0.72, 0.93] | 99.3% | 2.6% |
| Strongly agree | 1.27 [1.24, 1.31] | 100% | 0% | 1.31 [1.19, 1.49] | 100% | 0% |
| I don't know | 0.65 [0.59, 0.72] | 100% | 0% | 0.63 [0.47, 0.79] | 99.8% | 0.3% |
| Missing | 1.02 [0.71, 1.25] | 55.4% | 22.9% | 1.15 [0.52, 1.49] | 68.7% | 10.1% |

Estimated factor association with MPX vaccine acceptance, unadjusted or adjusted by country of residence. (*continued*)

| Question | RR [90% CrI] | pD | pROPE | RR [90% CrI] | pD | pROPE |
|---|-------------------|------|-------|-------------------|-------|-------|
| Worried about being treated differently due to MPX | | | | | | |
| Yes | 1.16 [1.15, 1.18] | 100% | 0% | 1.23 [1.14, 1.35] | 100% | 0% |
| I don't know | 1.04 [1.03, 1.06] | 100% | 82.9% | 1.1 [1.04, 1.17] | 99.8% | 6.8% |
| Prefer not to answer | 0.83 [0.76, 0.9] | 100% | 0.1% | 0.84 [0.69, 0.98] | 96.4% | 8.1% |
| Missing | 1.15 [1.13, 1.16] | 100% | 0% | 1.07 [0.62, 1.33] | 62.9% | 17.2% |

S8. Factor association with MPX vaccine acceptance by European subregion and country.

The following table report the estimated associations as in S7 but at the European subregion level. We highlighted respectively in red or green the estimates whose 50% CrI is lower or higher than the same interval at the level of the global estimates.

Estimated factor association with MPX vaccine acceptance at the regional level

| Question | Value | Location | Estimate | [90% CrI] | pD | pROPE | Sig. Diff. |
|----------|-------|----------------------|----------|--------------|-------|-------|------------|
| Age | 30-39 | Northern Europe | 1.03 | [1, 1.05] | 96.4% | 94% | average |
| | | Mediterranean Europe | 1.03 | [1, 1.05] | 96.2% | 95.4% | average |
| | | Baltics | 1.04 | [1, 1.09] | 93.5% | 69.8% | average |
| | | Western Europe | 1.04 | [1.02, 1.07] | 99.8% | 73.9% | average |
| | | Eastern Europe | 1.04 | [0.96, 1.1] | 82.2% | 58.3% | average |
| | | Central Europe | 1.04 | [0.98, 1.09] | 87.6% | 58.5% | average |
| | | South-East Europe | 1.06 | [1, 1.12] | 95.4% | 39% | average |
| | 40-49 | Northern Europe | 1.04 | [1.02, 1.06] | 99.5% | 79.5% | average |
| | | Western Europe | 1.04 | [1.02, 1.07] | 99.7% | 65.1% | average |
| | | Mediterranean Europe | 1.05 | [1.02, 1.07] | 99.9% | 62% | average |
| | | Baltics | 1.05 | [1.01, 1.1] | 96.1% | 51.4% | average |
| | | Eastern Europe | 1.07 | [0.99, 1.13] | 92.2% | 28.7% | average |
| | | Central Europe | 1.08 | [1.02, 1.13] | 97.7% | 20.3% | average |
| | | South-East Europe | 1.08 | [1.01, 1.14] | 97% | 19.6% | average |
| | 50-84 | Mediterranean Europe | 1.03 | [0.99, 1.07] | 92.5% | 78.4% | average |
| | | Northern Europe | 1.04 | [1.01, 1.08] | 98.5% | 67.4% | average |
| | | Western Europe | 1.04 | [1.01, 1.07] | 97.7% | 67.9% | average |
| | | Baltics | 1.04 | [0.94, 1.11] | 84.1% | 53.3% | average |
| | | Eastern Europe | 1.05 | [0.84, 1.14] | 70% | 33% | average |
| | | South-East Europe | 1.10 | [1, 1.2] | 95.7% | 17.9% | average |
| | | Central Europe | 1.10 | [1.02, 1.2] | 97.3% | 15.4% | average |

| | | | | | | | |
|---------|----------------------|----------------------|----------------------|--------------|--------------|-------|---------|
| ChemSex | Chemsex yes | Northern Europe | 1.03 | [0.98, 1.07] | 86.1% | 74.8% | lower |
| | | Eastern Europe | 1.07 | [0.87, 1.19] | 74% | 28.7% | average |
| | | Western Europe | 1.07 | [1.04, 1.09] | 100% | 10.6% | average |
| | | Mediterranean Europe | 1.08 | [1.05, 1.11] | 100% | 6.8% | average |
| | | Baltics | 1.10 | [1.02, 1.21] | 97.2% | 13.3% | average |
| | | Central Europe | 1.14 | [1.04, 1.22] | 98.9% | 5.7% | average |
| | | South-East Europe | 1.23 | [1.14, 1.35] | 100% | 0.1% | higher |
| | | Prefer not to answer | Mediterranean Europe | 1.00 | [0.9, 1.06] | 50.7% | 71.2% |
| | Baltics | | 1.01 | [0.66, 1.12] | 54.3% | 46.5% | average |
| | Western Europe | | 1.02 | [0.94, 1.07] | 65.7% | 74.6% | average |
| | Northern Europe | | 1.02 | [0.93, 1.07] | 65.7% | 73.9% | average |
| | South-East Europe | | 1.05 | [0.84, 1.23] | 69.2% | 30.6% | average |
| | Central Europe | | 1.09 | [0.92, 1.26] | 82.8% | 26% | average |
| | Eastern Europe | | 1.15 | [0.97, 1.39] | 90.9% | 16.2% | average |
| | Missing | | Western Europe | 1.08 | [0.8, 1.16] | 75.8% | 23.5% |
| | | Northern Europe | 1.09 | [0.95, 1.15] | 89% | 22.9% | average |
| | | Mediterranean Europe | 1.11 | [0.96, 1.18] | 90.6% | 17.7% | average |
| | | Baltics | 1.12 | [0.73, 1.27] | 80.7% | 15.2% | average |
| | | Central Europe | 1.22 | [0.71, 1.47] | 80.4% | 8.6% | average |
| | | South-East Europe | 1.25 | [0.52, 1.53] | 78.5% | 7.9% | average |
| | | Eastern Europe | 1.29 | [0.85, 1.53] | 88.2% | 6.9% | average |
| | | | Central Europe | 0.43 | [0.33, 0.54] | 100% | 0% |
| | Eastern Europe | | 0.47 | [0.37, 0.65] | 100% | 0% | average |
| | South-East Europe | | 0.48 | [0.37, 0.58] | 100% | 0% | average |
| | Baltics | | 0.55 | [0.39, 0.71] | 99.9% | 0.1% | average |
| | Mediterranean Europe | | 0.59 | [0.48, 0.69] | 100% | 0% | average |
| | Western Europe | | 0.60 | [0.49, 0.7] | 100% | 0% | average |

Slightly disagree

| | | | | | | |
|----------------------------|----------------------|------|--------------|-------|------|---------|
| | Northern Europe | 0.62 | [0.49, 0.75] | 100% | 0% | average |
| | Central Europe | 0.28 | [0.21, 0.38] | 100% | 0% | lower |
| | Eastern Europe | 0.29 | [0.2, 0.41] | 100% | 0% | average |
| | South-East Europe | 0.30 | [0.2, 0.38] | 100% | 0% | average |
| | Baltics | 0.40 | [0.27, 0.61] | 99.8% | 0.1% | average |
| Neither disagree nor agree | Mediterranean Europe | 0.42 | [0.34, 0.53] | 100% | 0% | average |
| | Western Europe | 0.43 | [0.33, 0.52] | 100% | 0% | average |
| | Northern Europe | 0.44 | [0.32, 0.56] | 100% | 0% | average |
| | Central Europe | 0.75 | [0.6, 0.89] | 99.6% | 1.1% | average |
| | South-East Europe | 0.77 | [0.63, 0.89] | 99.8% | 0.6% | average |
| | Eastern Europe | 0.79 | [0.65, 0.97] | 96.6% | 5.1% | average |
| | Baltics | 0.85 | [0.69, 0.99] | 96% | 8.7% | average |
| Slightly agree | Mediterranean Europe | 0.85 | [0.75, 0.93] | 99.8% | 2.7% | average |
| | Northern Europe | 0.87 | [0.76, 0.96] | 98.8% | 6.4% | average |
| | Western Europe | 0.92 | [0.83, 1.03] | 89.8% | 28% | higher |
| | Northern Europe | 1.20 | [1.12, 1.31] | 100% | 0% | lower |
| | Western Europe | 1.22 | [1.15, 1.32] | 100% | 0% | lower |
| | Mediterranean Europe | 1.23 | [1.15, 1.33] | 100% | 0% | average |
| | Baltics | 1.26 | [1.12, 1.45] | 99.8% | 0.6% | average |
| Strongly agree | South-East Europe | 1.40 | [1.28, 1.59] | 100% | 0% | average |
| | Eastern Europe | 1.50 | [1.32, 1.77] | 100% | 0% | higher |
| | Central Europe | 1.51 | [1.34, 1.73] | 100% | 0% | higher |
| | Central Europe | 0.48 | [0.29, 0.65] | 100% | 0% | lower |
| | South-East Europe | 0.53 | [0.36, 0.69] | 100% | 0% | average |
| | Mediterranean Europe | 0.62 | [0.47, 0.75] | 100% | 0% | average |
| | Eastern Europe | 0.62 | [0.45, 0.87] | 99% | 1.5% | average |

| | | | | | | | |
|---------------------|------------------------|----------------------|---------------|--------------|-------|---------|---------|
| I don't know | Baltics | 0.63 | [0.32, 0.88] | 98.9% | 1.5% | average | |
| | Northern Europe | 0.75 | [0.58, 0.95] | 97.9% | 4% | average | |
| | Western Europe | 0.78 | [0.65, 0.93] | 99.4% | 3% | higher | |
| Missing | South-East Europe | 0.58 | [0.026, 1.35] | 76.3% | 6.4% | average | |
| | Mediterranean Europe | 1.04 | [0.49, 1.31] | 56.2% | 14.3% | average | |
| | Baltics | 1.12 | [0.17, 1.48] | 62.3% | 8.5% | average | |
| | Central Europe | 1.14 | [0.075, 1.87] | 57.5% | 5.4% | average | |
| | Northern Europe | 1.16 | [0.62, 1.35] | 74.5% | 10.8% | average | |
| | Western Europe | 1.22 | [0.88, 1.37] | 89% | 7.7% | average | |
| | Eastern Europe | 1.41 | [0.51, 1.95] | 77.7% | 5.3% | average | |
| | Eastern Europe | 1.05 | [0.92, 1.17] | 76.6% | 40.1% | average | |
| | Baltics | 1.05 | [0.83, 1.14] | 73.8% | 32.2% | average | |
| | Northern Europe | 1.07 | [1.04, 1.11] | 100% | 9.8% | average | |
| | Western Europe | 1.08 | [1.06, 1.1] | 100% | 1.7% | average | |
| | Mediterranean Europe | 1.09 | [1.06, 1.12] | 100% | 0.4% | average | |
| HIV+ on ART | Central Europe | 1.15 | [1.08, 1.23] | 99.8% | 1.7% | average | |
| | South-East Europe | 1.19 | [1.1, 1.28] | 99.9% | 0.5% | higher | |
| | South-East Europe | 0.91 | [0.63, 1.14] | 73.1% | 23.2% | average | |
| | Northern Europe | 0.91 | [0.63, 1.02] | 88.4% | 33.6% | average | |
| | Western Europe | 0.94 | [0.8, 1.03] | 85.4% | 42.6% | average | |
| | Baltics | 0.99 | [0.73, 1.17] | 54.4% | 36.5% | average | |
| | HIV+ not on ART | Eastern Europe | 1.00 | [0.76, 1.25] | 50% | 26.8% | average |
| | | Central Europe | 1.00 | [0.78, 1.23] | 50.3% | 29.1% | average |
| | | Mediterranean Europe | 1.01 | [0.9, 1.12] | 56.4% | 52.6% | average |
| | | Central Europe | 0.86 | [0.77, 0.95] | 99.4% | 4.4% | average |
| | | Eastern Europe | 0.87 | [0.77, 1] | 95.3% | 12.4% | average |
| | | South-East Europe | 0.89 | [0.8, 1.01] | 94.2% | 17.2% | average |

| | | | | | | | | |
|----------------------|-----------------------------|----------------------|----------------------|--------------|--------------|---------|---------|---------|
| HIVStatus | HIV status unknown | Western Europe | 0.91 | [0.85, 0.95] | 100% | 5.2% | average | |
| | | Baltics | 0.91 | [0.79, 1] | 95.1% | 18.6% | average | |
| | | Mediterranean Europe | 0.92 | [0.87, 0.96] | 100% | 7.7% | average | |
| | | Northern Europe | 0.94 | [0.87, 0.99] | 97.8% | 30.5% | average | |
| | Prefer not to answer | Eastern Europe | 0.92 | [0.75, 1.12] | 77.7% | 25.7% | average | |
| | | Western Europe | 0.92 | [0.83, 0.99] | 98.1% | 26.1% | average | |
| | | South-East Europe | 0.93 | [0.78, 1.1] | 78.3% | 28.1% | average | |
| | | Central Europe | 0.93 | [0.79, 1.11] | 76.2% | 30.4% | average | |
| | | Baltics | 0.94 | [0.75, 1.05] | 84% | 36.5% | average | |
| | | Mediterranean Europe | 0.95 | [0.89, 1.01] | 89.9% | 52.5% | average | |
| | | Northern Europe | 0.96 | [0.87, 1.03] | 84.9% | 57.4% | average | |
| | | Missing | Baltics | 0.83 | [0.13, 1.08] | 80.8% | 20.9% | average |
| | | | Central Europe | 0.93 | [0.36, 1.29] | 62.3% | 17.1% | average |
| | | | Mediterranean Europe | 0.96 | [0.79, 1.07] | 70.6% | 46.5% | average |
| | | | Eastern Europe | 0.96 | [0.45, 1.33] | 56.9% | 17.8% | average |
| | | | South-East Europe | 1.02 | [0.7, 1.31] | 54.7% | 22% | average |
| | Northern Europe | | 1.04 | [0.89, 1.14] | 71.1% | 40.2% | average | |
| | Western Europe | | 1.05 | [0.92, 1.15] | 74.8% | 39% | average | |
| | Yes, only me | | Central Europe | 0.92 | [0.52, 1.21] | 63.1% | 16.9% | average |
| | | Northern Europe | 1.03 | [0.8, 1.11] | 62.1% | 40.6% | average | |
| Mediterranean Europe | | 1.08 | [1, 1.14] | 94.8% | 23% | average | | |
| Baltics | | 1.09 | [0.78, 1.25] | 78.1% | 19.8% | average | | |
| Western Europe | | 1.10 | [1.04, 1.16] | 99.4% | 6.9% | average | | |
| Eastern Europe | | 1.17 | [0.69, 1.47] | 77.6% | 10.9% | average | | |
| South-East Europe | | 1.18 | [0.84, 1.44] | 83.4% | 11.7% | average | | |
| Northern Europe | | 1.07 | [1, 1.12] | 95.1% | 21.6% | lower | | |
| Mediterranean Europe | | 1.09 | [1.05, 1.13] | 99.6% | 6.7% | lower | | |

| | | | | | | |
|-----------------------------------|----------------------|---------------|---------------|-------|---------|---------|
| Yes, me and someone I know | Western Europe | 1.10 | [1.06, 1.14] | 100% | 1.6% | average |
| | Baltics | 1.12 | [1.03, 1.23] | 96.8% | 7.4% | average |
| | Central Europe | 1.22 | [1.02, 1.38] | 95.8% | 4.3% | average |
| | Eastern Europe | 1.23 | [1.02, 1.4] | 95.7% | 3.9% | average |
| | South-East Europe | 1.25 | [1.09, 1.46] | 98.4% | 2.2% | higher |
| Yes, only someone I know | Northern Europe | 1.12 | [1.09, 1.15] | 100% | 0% | lower |
| | Western Europe | 1.13 | [1.1, 1.15] | 100% | 0% | lower |
| | Mediterranean Europe | 1.13 | [1.1, 1.16] | 100% | 0% | lower |
| | Baltics | 1.16 | [1.09, 1.25] | 99.6% | 1.1% | average |
| | South-East Europe | 1.30 | [1.19, 1.39] | 100% | 0.1% | higher |
| | Central Europe | 1.30 | [1.22, 1.39] | 100% | 0% | higher |
| | Eastern Europe | 1.32 | [1.23, 1.45] | 100% | 0.1% | higher |
| I don't know | Northern Europe | 1.03 | [1, 1.06] | 94.3% | 88.3% | average |
| | Western Europe | 1.04 | [1.01, 1.06] | 98.1% | 80.7% | average |
| | Baltics | 1.04 | [0.99, 1.1] | 91.9% | 58.3% | average |
| | Mediterranean Europe | 1.04 | [1.02, 1.08] | 99.5% | 64.4% | average |
| | South-East Europe | 1.07 | [0.98, 1.14] | 89.9% | 32.9% | average |
| | Eastern Europe | 1.07 | [0.97, 1.14] | 89.9% | 32.1% | average |
| | Central Europe | 1.07 | [0.99, 1.15] | 94.1% | 27.1% | average |
| Prefer not to answer | Central Europe | 0.33 | [0.018, 0.94] | 96.6% | 2.6% | lower |
| | South-East Europe | 0.58 | [0.12, 1.12] | 89.2% | 5.6% | average |
| | Eastern Europe | 0.67 | [0.046, 1.42] | 75.2% | 6.3% | average |
| | Western Europe | 0.77 | [0.42, 1.01] | 94.1% | 10.7% | average |
| | Baltics | 0.85 | [0.11, 1.21] | 70% | 13.1% | average |
| | Northern Europe | 1.03 | [0.73, 1.16] | 58.3% | 26.1% | average |
| | Mediterranean Europe | 1.03 | [0.82, 1.13] | 62.4% | 37.1% | higher |
| Eastern Europe | 0.57 | [0.042, 1.17] | 87.8% | 5.9% | average | |

| | | | | | | | |
|----------------|----------------|----------------------|------|---------------|-------|-------|---------|
| | | Central Europe | 0.66 | [0.053, 1.35] | 78.6% | 6.7% | average |
| | | South-East Europe | 0.67 | [0.16, 1.24] | 82% | 7.3% | average |
| | | Northern Europe | 0.73 | [0.073, 1.05] | 89.6% | 12.7% | average |
| | Missing | Baltics | 0.78 | [0.1, 1.17] | 78.2% | 11.9% | average |
| | | Western Europe | 0.83 | [0.39, 1.1] | 82.5% | 17% | average |
| | | Mediterranean Europe | 0.95 | [0.64, 1.14] | 64.6% | 25.8% | average |
| | | Northern Europe | 1.01 | [0.99, 1.03] | 84.9% | 99.3% | average |
| | | Western Europe | 1.02 | [1, 1.04] | 96.6% | 97.7% | average |
| | | Mediterranean Europe | 1.02 | [1, 1.05] | 96% | 95.3% | average |
| Migrant | Yes | Baltics | 1.03 | [0.99, 1.08] | 90.8% | 82.4% | average |
| | | Central Europe | 1.04 | [0.96, 1.09] | 82.2% | 60.6% | average |
| | | Eastern Europe | 1.04 | [0.97, 1.1] | 86.3% | 55.3% | average |
| | | South-East Europe | 1.04 | [0.97, 1.1] | 86.8% | 55.7% | average |
| | | Northern Europe | 1.00 | [0.82, 1.09] | 51.8% | 50.6% | average |
| | | Baltics | 1.00 | [0.5, 1.18] | 51% | 25.5% | average |
| | | Western Europe | 1.04 | [0.89, 1.13] | 71.4% | 40.2% | average |
| | | Eastern Europe | 1.06 | [0.49, 1.39] | 59.5% | 14.6% | average |
| | | Mediterranean Europe | 1.07 | [0.87, 1.18] | 77% | 27.7% | average |
| | Baltics | South-East Europe | 1.11 | [0.44, 1.47] | 65.7% | 11.6% | average |
| | | Central Europe | 1.24 | [0.88, 1.5] | 86.4% | 9.8% | average |
| | | Northern Europe | 1.08 | [0.98, 1.14] | 91.8% | 22.4% | average |
| | | Mediterranean Europe | 1.09 | [0.98, 1.15] | 91.2% | 23.4% | average |
| | | Western Europe | 1.09 | [0.99, 1.15] | 94.1% | 18.8% | average |
| | | Baltics | 1.12 | [0.86, 1.26] | 86.5% | 13.1% | average |
| | | Central Europe | 1.25 | [0.75, 1.5] | 86.4% | 6.8% | average |
| | | Eastern Europe | 1.27 | [0.88, 1.52] | 89.6% | 6.7% | average |

Caribbean

| | | | | | | |
|------------------------|----------------------|------|--------------|-------|-------|---------|
| | South-East Europe | 1.28 | [0.89, 1.52] | 90% | 6.3% | average |
| Central America | Northern Europe | 1.08 | [0.95, 1.13] | 89.3% | 22.1% | lower |
| | Western Europe | 1.10 | [1.03, 1.15] | 97.9% | 9.9% | average |
| | Mediterranean Europe | 1.13 | [1.06, 1.18] | 99.6% | 2.7% | average |
| | Baltics | 1.13 | [0.8, 1.26] | 87% | 10.1% | average |
| | Central Europe | 1.25 | [0.79, 1.44] | 86.6% | 6.6% | average |
| | Eastern Europe | 1.27 | [0.68, 1.49] | 86.7% | 4.6% | average |
| | South-East Europe | 1.28 | [0.7, 1.49] | 87% | 5% | average |
| Central Europe | South-East Europe | 0.87 | [0.5, 1.06] | 87.7% | 17.6% | average |
| | Mediterranean Europe | 0.92 | [0.78, 1] | 95% | 28.8% | average |
| | Eastern Europe | 0.93 | [0.75, 1.14] | 72.2% | 28.1% | average |
| | Central Europe | 0.94 | [0.8, 1.09] | 75% | 34.5% | average |
| | Baltics | 0.96 | [0.76, 1.11] | 72.7% | 41.2% | average |
| | Western Europe | 0.97 | [0.91, 1.03] | 79.1% | 69.3% | average |
| | Northern Europe | 0.97 | [0.9, 1.04] | 74% | 69.6% | average |
| Eastern Europe | Central Europe | 0.90 | [0.68, 1.06] | 84.7% | 24.9% | average |
| | Mediterranean Europe | 0.94 | [0.76, 1.03] | 84.7% | 43% | average |
| | Western Europe | 0.95 | [0.82, 1.02] | 86.6% | 45.7% | average |
| | Northern Europe | 1.00 | [0.92, 1.09] | 51.9% | 68.7% | average |
| | Baltics | 1.00 | [0.88, 1.15] | 51.8% | 49.8% | average |
| | South-East Europe | 1.01 | [0.81, 1.25] | 52.4% | 30.7% | average |
| | Eastern Europe | 1.02 | [0.86, 1.17] | 56.7% | 41.3% | average |
| | Mediterranean Europe | 0.98 | [0.82, 1.06] | 64.6% | 54.9% | average |
| | Northern Europe | 1.01 | [0.92, 1.08] | 60.6% | 72.2% | average |
| | Western Europe | 1.02 | [0.95, 1.07] | 69.3% | 76.6% | average |
| | Baltics | 1.04 | [0.83, 1.2] | 68.5% | 38.6% | average |
| | Eastern Europe | 1.06 | [0.72, 1.35] | 66% | 23.1% | average |

Eastern Mediterranean

| | | | | | | |
|-----------------------------|----------------------|------|---------------|-------|-------|---------|
| | Central Europe | 1.13 | [0.88, 1.44] | 81.1% | 19.3% | average |
| | South-East Europe | 1.13 | [0.93, 1.36] | 85.5% | 18.6% | average |
| | Mediterranean Europe | 1.02 | [0.94, 1.08] | 69.7% | 72.5% | average |
| | Northern Europe | 1.03 | [0.96, 1.08] | 80.8% | 75.1% | average |
| | South-East Europe | 1.03 | [0.7, 1.2] | 59.8% | 28% | average |
| | Western Europe | 1.04 | [1, 1.09] | 95.6% | 59.4% | average |
| Mediterranean Europe | Baltics | 1.05 | [0.92, 1.18] | 81.4% | 43.3% | average |
| | Central Europe | 1.06 | [0.8, 1.23] | 69.8% | 28.3% | average |
| | Eastern Europe | 1.10 | [0.89, 1.36] | 82.2% | 21.6% | average |
| | Mediterranean Europe | 1.05 | [0.95, 1.11] | 82.5% | 45.5% | average |
| | Northern Europe | 1.05 | [0.99, 1.11] | 92.3% | 43.8% | average |
| | Western Europe | 1.06 | [1, 1.11] | 95.8% | 34% | average |
| Northern America | Baltics | 1.09 | [0.95, 1.24] | 89.8% | 19.6% | average |
| | Eastern Europe | 1.14 | [0.7, 1.38] | 79.5% | 12% | average |
| | Central Europe | 1.17 | [0.75, 1.43] | 84.6% | 10.3% | average |
| | South-East Europe | 1.24 | [1.03, 1.5] | 96.4% | 5.5% | average |
| | Central Europe | 0.81 | [0.087, 1.24] | 69.5% | 12.8% | average |
| | Baltics | 1.01 | [0.62, 1.18] | 53.7% | 28.7% | average |
| | Northern Europe | 1.01 | [0.91, 1.08] | 61.4% | 67.3% | average |
| | South-East Europe | 1.03 | [0.19, 1.44] | 54.2% | 12.5% | average |
| Northern Europe | Mediterranean Europe | 1.03 | [0.83, 1.14] | 64.7% | 39% | average |
| | Eastern Europe | 1.03 | [0.21, 1.44] | 55% | 12.9% | average |
| | Western Europe | 1.09 | [0.99, 1.16] | 92.6% | 23.2% | average |
| | Northern Europe | 1.08 | [1.03, 1.12] | 98.8% | 11.4% | lower |
| | Western Europe | 1.10 | [1.07, 1.14] | 100% | 1.2% | lower |
| | Mediterranean Europe | 1.10 | [1.07, 1.14] | 100% | 0.5% | lower |

| | | | | | | |
|---------------------------|----------------------|------|--------------|-------|-------|---------|
| | Baltics | 1.12 | [0.99, 1.23] | 94.5% | 6.4% | average |
| South America | Eastern Europe | 1.24 | [0.79, 1.39] | 89.4% | 4.6% | average |
| | South-East Europe | 1.26 | [1.05, 1.42] | 96.7% | 2.8% | higher |
| | Central Europe | 1.27 | [1.12, 1.45] | 98.8% | 1.5% | higher |
| | Northern Europe | 0.91 | [0.68, 1.04] | 86.1% | 30.8% | average |
| South-East Asia | South-East Europe | 0.92 | [0.4, 1.33] | 62% | 15.2% | average |
| | Eastern Europe | 0.98 | [0.54, 1.37] | 54.3% | 16.1% | average |
| | Baltics | 0.98 | [0.49, 1.2] | 56.2% | 25.6% | average |
| | Western Europe | 0.99 | [0.85, 1.09] | 57.2% | 52% | average |
| | Mediterranean Europe | 1.03 | [0.84, 1.17] | 60.2% | 33.1% | average |
| | Central Europe | 1.08 | [0.68, 1.47] | 61.3% | 14.5% | average |
| | Eastern Europe | 0.86 | [0.58, 1.06] | 89.7% | 13.5% | average |
| South-East Europe | Central Europe | 0.91 | [0.74, 1.14] | 77.8% | 21% | average |
| | South-East Europe | 0.91 | [0.78, 1.06] | 83.3% | 26.4% | average |
| | Western Europe | 0.92 | [0.85, 0.98] | 99% | 21.3% | average |
| | Baltics | 0.93 | [0.73, 1.06] | 85.5% | 30.2% | average |
| | Mediterranean Europe | 0.93 | [0.82, 1] | 94.4% | 30.4% | average |
| | Northern Europe | 0.95 | [0.86, 1.01] | 91.6% | 47% | average |
| | Northern Europe | 0.96 | [0.72, 1.05] | 76.3% | 49.3% | average |
| Sub-Saharan Africa | Central Europe | 0.97 | [0.5, 1.36] | 55.9% | 20.5% | average |
| | Eastern Europe | 0.97 | [0.61, 1.31] | 55.8% | 21.9% | average |
| | Mediterranean Europe | 0.97 | [0.87, 1.06] | 67.6% | 58.3% | average |
| | Baltics | 0.98 | [0.62, 1.17] | 58.8% | 36.5% | average |
| | Western Europe | 0.98 | [0.89, 1.06] | 63.4% | 67% | average |
| | South-East Europe | 1.04 | [0.74, 1.43] | 57.5% | 20.5% | average |
| | Northern Europe | 1.01 | [0.96, 1.05] | 66.8% | 92.1% | average |
| | Eastern Europe | 1.01 | [0.75, 1.13] | 55.4% | 42.1% | average |

| | | | | | | |
|---------------------------|----------------------|------|--------------|-------|-------|---------|
| Western Europe | Mediterranean Europe | 1.01 | [0.96, 1.05] | 67.1% | 89.8% | average |
| | Baltics | 1.02 | [0.91, 1.11] | 68.3% | 66.2% | average |
| | South-East Europe | 1.02 | [0.85, 1.14] | 60.8% | 45.7% | average |
| | Western Europe | 1.02 | [0.99, 1.06] | 86.2% | 89.9% | average |
| | Central Europe | 1.04 | [0.89, 1.16] | 69.3% | 45.1% | average |
| Western Pacific | Northern Europe | 1.08 | [1.01, 1.13] | 96.5% | 18.2% | lower |
| | Western Europe | 1.11 | [1.06, 1.16] | 99.8% | 3.3% | lower |
| | Mediterranean Europe | 1.12 | [1.05, 1.18] | 98.7% | 5.3% | average |
| | Baltics | 1.15 | [1.02, 1.27] | 96.3% | 6.3% | average |
| | Central Europe | 1.29 | [1.02, 1.46] | 95.5% | 3.4% | average |
| | Eastern Europe | 1.32 | [1.07, 1.52] | 97.2% | 2.3% | higher |
| | South-East Europe | 1.32 | [1.07, 1.5] | 97.2% | 2.2% | higher |
| Slightly worried | Northern Europe | 1.37 | [1.28, 1.48] | 100% | 0% | lower |
| | Baltics | 1.54 | [1.34, 1.82] | 100% | 0% | average |
| | Mediterranean Europe | 1.58 | [1.47, 1.72] | 100% | 0% | average |
| | Western Europe | 1.61 | [1.5, 1.73] | 100% | 0% | average |
| | Eastern Europe | 1.89 | [1.66, 2.15] | 100% | 0% | higher |
| | Central Europe | 1.94 | [1.76, 2.17] | 100% | 0% | higher |
| | South-East Europe | 1.94 | [1.71, 2.19] | 100% | 0% | higher |
| Moderately worried | Northern Europe | 1.44 | [1.33, 1.58] | 100% | 0% | lower |
| | Baltics | 1.67 | [1.41, 2.04] | 100% | 0% | average |
| | Mediterranean Europe | 1.75 | [1.6, 1.94] | 100% | 0% | average |
| | Western Europe | 1.82 | [1.67, 2] | 100% | 0% | average |
| | Eastern Europe | 2.08 | [1.79, 2.45] | 100% | 0% | average |
| | Central Europe | 2.16 | [1.91, 2.47] | 100% | 0% | higher |
| | South-East Europe | 2.21 | [1.93, 2.57] | 100% | 0% | higher |

| | | | | | | |
|---------------------|----------------------|------|--------------|-------|-------|---------|
| Worried | Northern Europe | 1.49 | [1.37, 1.65] | 100% | 0% | lower |
| | Baltics | 1.75 | [1.45, 2.21] | 100% | 0% | average |
| | Mediterranean Europe | 1.82 | [1.65, 2.02] | 100% | 0% | average |
| | Western Europe | 1.96 | [1.79, 2.18] | 100% | 0% | average |
| | Eastern Europe | 2.30 | [1.96, 2.76] | 100% | 0% | average |
| | South-East Europe | 2.48 | [2.15, 2.92] | 100% | 0% | higher |
| | Central Europe | 2.56 | [2.24, 2.98] | 100% | 0% | higher |
| Very worried | Northern Europe | 1.50 | [1.38, 1.66] | 100% | 0% | lower |
| | Baltics | 1.79 | [1.47, 2.25] | 100% | 0% | average |
| | Mediterranean Europe | 1.89 | [1.71, 2.12] | 100% | 0% | average |
| | Western Europe | 1.98 | [1.8, 2.2] | 100% | 0% | average |
| | Eastern Europe | 2.37 | [2.01, 2.85] | 100% | 0% | average |
| | Central Europe | 2.54 | [2.21, 2.95] | 100% | 0% | higher |
| | South-East Europe | 2.55 | [2.2, 3] | 100% | 0% | higher |
| I don't know | Northern Europe | 1.17 | [1.06, 1.31] | 98.7% | 3.7% | average |
| | Central Europe | 1.21 | [0.92, 1.44] | 88.5% | 10.4% | average |
| | Baltics | 1.23 | [1.02, 1.5] | 95.7% | 4.7% | average |
| | Western Europe | 1.24 | [1.08, 1.4] | 99% | 2.3% | average |
| | Mediterranean Europe | 1.25 | [1.1, 1.41] | 99.5% | 1.4% | average |
| | Eastern Europe | 1.32 | [1.07, 1.64] | 97.8% | 2.9% | average |
| | South-East Europe | 1.37 | [1.13, 1.71] | 99.3% | 1.2% | average |
| | Northern Europe | 1.47 | [1.24, 1.65] | 98.9% | 0.6% | lower |
| | Baltics | 1.73 | [1.17, 2.25] | 96.6% | 0.8% | average |
| | Western Europe | 1.79 | [1.32, 2.08] | 99.2% | 0.5% | average |
| | Mediterranean Europe | 1.85 | [1.5, 2.13] | 99.9% | 0.1% | average |
| | Eastern Europe | 2.48 | [1.27, 3.15] | 96.5% | 0.4% | average |
| | Central Europe | 2.54 | [1.73, 3.11] | 99.6% | 0.1% | higher |

Missing

| | | | | | | |
|----------------------|----------------------|-----------------|--------------|--------------|------|---------|
| | South-East Europe | 2.63 | [1.35, 3.32] | 96.9% | 0.4% | higher |
| Slightly severe | Northern Europe | 1.59 | [1.43, 1.8] | 100% | 0% | lower |
| | Mediterranean Europe | 1.69 | [1.53, 1.87] | 100% | 0% | lower |
| | Baltics | 1.85 | [1.53, 2.31] | 100% | 0% | average |
| | Western Europe | 1.91 | [1.71, 2.16] | 100% | 0% | average |
| | Eastern Europe | 2.40 | [2.01, 2.84] | 100% | 0% | higher |
| | South-East Europe | 2.41 | [2.09, 2.82] | 100% | 0% | higher |
| | Central Europe | 2.43 | [2.11, 2.83] | 100% | 0% | higher |
| | Moderately severe | Northern Europe | 1.75 | [1.54, 2.02] | 100% | 0% |
| Mediterranean Europe | | 1.88 | [1.68, 2.13] | 100% | 0% | lower |
| Baltics | | 2.12 | [1.66, 2.76] | 100% | 0% | average |
| Western Europe | | 2.27 | [2, 2.63] | 100% | 0% | average |
| Eastern Europe | | 3.06 | [2.44, 3.79] | 100% | 0% | higher |
| South-East Europe | | 3.08 | [2.59, 3.69] | 100% | 0% | higher |
| Central Europe | | 3.21 | [2.73, 3.87] | 100% | 0% | higher |
| Severe | | Northern Europe | 1.82 | [1.59, 2.11] | 100% | 0% |
| | Mediterranean Europe | 1.97 | [1.74, 2.25] | 100% | 0% | lower |
| | Baltics | 2.25 | [1.73, 3.08] | 100% | 0% | average |
| | Western Europe | 2.49 | [2.16, 2.91] | 100% | 0% | average |
| | South-East Europe | 3.50 | [2.89, 4.28] | 100% | 0% | higher |
| | Eastern Europe | 3.55 | [2.8, 4.52] | 100% | 0% | higher |
| | Central Europe | 3.77 | [3.14, 4.65] | 100% | 0% | higher |
| | | Northern Europe | 1.89 | [1.64, 2.22] | 100% | 0% |
| | Mediterranean Europe | 2.06 | [1.81, 2.38] | 100% | 0% | lower |
| | Baltics | 2.23 | [1.63, 3.13] | 100% | 0% | average |
| | Western Europe | 2.57 | [2.22, 3.03] | 100% | 0% | average |

| | | | | | | |
|---------------------|----------------------|------|--------------|-------|-------|---------|
| Very severe | South-East Europe | 3.72 | [3.05, 4.63] | 100% | 0% | higher |
| | Eastern Europe | 3.88 | [3.02, 5.05] | 100% | 0% | higher |
| | Central Europe | 3.98 | [3.27, 4.96] | 100% | 0% | higher |
| I don't know | Northern Europe | 1.41 | [1.21, 1.63] | 100% | 0.2% | lower |
| | Mediterranean Europe | 1.50 | [1.33, 1.71] | 100% | 0% | lower |
| | Baltics | 1.66 | [1.3, 2.15] | 99.7% | 0.3% | average |
| | Western Europe | 1.71 | [1.49, 1.98] | 100% | 0% | average |
| | Central Europe | 2.17 | [1.81, 2.66] | 100% | 0% | higher |
| | South-East Europe | 2.20 | [1.83, 2.74] | 100% | 0% | higher |
| | Eastern Europe | 2.37 | [1.87, 3.19] | 100% | 0% | higher |
| Missing | Northern Europe | 1.71 | [1.21, 2.12] | 98.5% | 0.8% | average |
| | Western Europe | 1.76 | [0.78, 2.48] | 90.3% | 2.6% | average |
| | Mediterranean Europe | 1.86 | [1.27, 2.3] | 98.7% | 0.7% | average |
| | Baltics | 1.98 | [1.13, 2.96] | 96.7% | 1% | average |
| | Eastern Europe | 2.26 | [0.34, 4.08] | 84.7% | 1.9% | average |
| | Central Europe | 2.60 | [1.1, 4.17] | 96.2% | 1.1% | average |
| | South-East Europe | 2.61 | [0.66, 4.29] | 91.4% | 1.2% | average |
| PrEP yes | Mediterranean Europe | 1.13 | [1.1, 1.16] | 100% | 0% | lower |
| | Western Europe | 1.14 | [1.11, 1.17] | 100% | 0% | lower |
| | Northern Europe | 1.14 | [1.11, 1.18] | 100% | 0% | lower |
| | Baltics | 1.16 | [1.09, 1.27] | 99.9% | 0.5% | average |
| | South-East Europe | 1.21 | [1.06, 1.31] | 98.7% | 3.3% | average |
| | Eastern Europe | 1.24 | [1.12, 1.34] | 99.9% | 0.7% | average |
| | Central Europe | 1.29 | [1.19, 1.38] | 100% | 0% | higher |
| | South-East Europe | 0.94 | [0.76, 1.12] | 70.9% | 31.9% | average |
| | Baltics | 0.95 | [0.72, 1.05] | 78.7% | 43.4% | average |

| | | | | | | |
|-----------------------------|----------------------|------|--------------|-------|-------|---------|
| Missing | Eastern Europe | 0.95 | [0.77, 1.13] | 68.2% | 34.3% | average |
| | Mediterranean Europe | 0.96 | [0.86, 1.04] | 77.6% | 55.8% | average |
| | Western Europe | 0.96 | [0.85, 1.05] | 75.9% | 55% | average |
| | Central Europe | 0.96 | [0.77, 1.19] | 62.4% | 31.6% | average |
| | Northern Europe | 0.97 | [0.84, 1.05] | 75% | 56.1% | average |
| STI yes | Northern Europe | 1.08 | [1.06, 1.11] | 100% | 0.9% | lower |
| | Mediterranean Europe | 1.09 | [1.07, 1.12] | 100% | 0.3% | lower |
| | Western Europe | 1.10 | [1.08, 1.12] | 100% | 0% | lower |
| | Baltics | 1.11 | [1.05, 1.19] | 99.1% | 4.8% | average |
| | Eastern Europe | 1.18 | [1.06, 1.26] | 99% | 3.3% | average |
| | South-East Europe | 1.20 | [1.12, 1.27] | 100% | 0.1% | higher |
| | Central Europe | 1.22 | [1.15, 1.29] | 100% | 0% | higher |
| | South-East Europe | 0.95 | [0.81, 1.06] | 79.3% | 40.4% | average |
| | Northern Europe | 0.96 | [0.84, 1.01] | 90% | 58% | average |
| | Central Europe | 0.96 | [0.83, 1.11] | 70.2% | 42.1% | average |
| STI unknown | Mediterranean Europe | 0.97 | [0.9, 1.01] | 87.2% | 67.8% | average |
| | Baltics | 0.97 | [0.83, 1.07] | 75% | 56% | average |
| | Western Europe | 0.97 | [0.91, 1.03] | 80.6% | 75.5% | average |
| | Eastern Europe | 0.99 | [0.87, 1.15] | 56.8% | 44.3% | average |
| | Western Europe | 0.89 | [0.69, 1.01] | 93.3% | 21.3% | average |
| | Mediterranean Europe | 0.92 | [0.78, 1.02] | 89.5% | 32.4% | average |
| | Central Europe | 0.93 | [0.65, 1.21] | 67.4% | 21.5% | average |
| Prefer not to answer | Eastern Europe | 0.94 | [0.58, 1.31] | 61.3% | 17.6% | average |
| | Baltics | 0.94 | [0.6, 1.16] | 68.2% | 27.6% | average |
| | Northern Europe | 0.97 | [0.79, 1.12] | 62.7% | 40.2% | average |
| | South-East Europe | 1.03 | [0.75, 1.36] | 56.4% | 19.3% | average |
| | Northern Europe | 1.07 | [0.96, 1.15] | 89.4% | 27.7% | average |

| | | | | | | |
|-----------------------------|----------------------|------|--------------|-------|-------|---------|
| Missing | Mediterranean Europe | 1.08 | [0.92, 1.17] | 84.8% | 27.2% | average |
| | Western Europe | 1.08 | [0.94, 1.16] | 87.3% | 26.2% | average |
| | Baltics | 1.10 | [0.91, 1.25] | 86.8% | 18.9% | average |
| | Central Europe | 1.16 | [0.94, 1.34] | 89.9% | 12.6% | average |
| | South-East Europe | 1.18 | [0.84, 1.44] | 85% | 10.8% | average |
| | Eastern Europe | 1.22 | [0.93, 1.5] | 90.8% | 8.5% | average |
| Yes | Northern Europe | 1.11 | [1.08, 1.14] | 100% | 0% | lower |
| | Mediterranean Europe | 1.14 | [1.11, 1.18] | 100% | 0% | lower |
| | Western Europe | 1.15 | [1.12, 1.19] | 100% | 0% | lower |
| | Baltics | 1.20 | [1.12, 1.33] | 100% | 0.1% | average |
| | Eastern Europe | 1.33 | [1.23, 1.44] | 100% | 0% | higher |
| | Central Europe | 1.38 | [1.3, 1.49] | 100% | 0% | higher |
| | South-East Europe | 1.41 | [1.32, 1.53] | 100% | 0% | higher |
| | Northern Europe | 1.03 | [0.99, 1.06] | 89.3% | 83.2% | lower |
| I don't know | Western Europe | 1.05 | [1.02, 1.09] | 99.5% | 47.1% | lower |
| | Mediterranean Europe | 1.06 | [1.03, 1.1] | 99.9% | 24.4% | average |
| | Baltics | 1.09 | [1.02, 1.18] | 97% | 16.5% | average |
| | South-East Europe | 1.16 | [1.07, 1.25] | 99.8% | 2.7% | average |
| | Central Europe | 1.19 | [1.11, 1.28] | 100% | 0.1% | higher |
| | Eastern Europe | 1.19 | [1.1, 1.3] | 100% | 0.2% | higher |
| | South-East Europe | 0.80 | [0.59, 1.08] | 89.2% | 10.6% | average |
| | Western Europe | 0.80 | [0.63, 0.93] | 99.8% | 2.1% | average |
| Prefer not to answer | Eastern Europe | 0.81 | [0.61, 1.09] | 87.6% | 11.8% | average |
| | Baltics | 0.85 | [0.6, 1.07] | 88.8% | 12.9% | average |
| | Central Europe | 0.86 | [0.66, 1.12] | 82.2% | 15.7% | average |
| | Mediterranean Europe | 0.87 | [0.75, 0.96] | 98.9% | 7.5% | average |
| | Northern Europe | 0.90 | [0.76, 1.02] | 91.6% | 20.4% | average |


| | | | | | | |
|----------------|----------------------|------|---------------|-------|-------|---------|
| Missing | Central Europe | 0.29 | [0.072, 0.88] | 97% | 1.3% | lower |
| | Eastern Europe | 0.93 | [0.21, 1.55] | 56% | 8.6% | average |
| | Baltics | 0.94 | [0.29, 1.31] | 57.2% | 12.7% | average |
| | Mediterranean Europe | 1.06 | [0.9, 1.18] | 75.5% | 34.9% | average |
| | Northern Europe | 1.14 | [0.98, 1.21] | 93.1% | 9.5% | average |
| | Western Europe | 1.20 | [1.11, 1.27] | 99.8% | 0.8% | average |
| | South-East Europe | 1.22 | [0.32, 1.83] | 64.3% | 5.9% | average |

S9. Association plot


In this figure are shown the posterior RR distributions of the associations between the factors of interest and the MPX vaccine acceptance, divided by type of global estimate (country/subregion adjusted and unadjusted). Also, the estimates at the level of each European subregion are presented. The bars for each factor value represent the 90% CrI (with horizontal markers at 50% and 90% levels). The global estimates are distinguished by a triangle while the subregional ones by points.

For readability reasons, the plot for the impact of the region of origin/birth of migrants is plotted separately.

General plot



Migrant birth region plot



S10. Session Info

R version 4.2.0 (2022-04-22)

Platform: aarch64-apple-darwin20 (64-bit)

locale: en_US.UTF-8|en_US.UTF-8|en_US.UTF-8|C|en_US.UTF-8|en_US.UTF-8

attached base packages: *parallel*, *stats*, *graphics*, *grDevices*, *utils*, *datasets*, *methods* and *base*

other attached packages: *pander*(v.0.6.5), *knitr*(v.1.40), *kableExtra*(v.1.3.4), *brms*(v.2.17.0), *Rcpp*(v.1.0.8.3), *here*(v.1.0.1), *rlang*(v.1.0.4), *readxl*(v.1.4.0), *purrr*(v.0.3.4), *tidyr*(v.1.2.0), *stringr*(v.1.4.0), *readr*(v.2.1.2), *ggplot2*(v.3.3.6) and *dplyr*(v.1.0.9)

loaded via a namespace (and not attached): *backports*(v.1.4.1), *Hmisc*(v.4.7-0), *systemfonts*(v.1.0.4), *plyr*(v.1.8.7), *igraph*(v.1.3.1), *splines*(v.4.2.0), *crosstalk*(v.1.2.0), *rstantools*(v.2.2.0), *inline*(v.0.3.19), *digest*(v.0.6.29), *htmltools*(v.0.5.2), *fansi*(v.1.0.3), *magrittr*(v.2.0.3), *checkmate*(v.2.1.0), *cluster*(v.2.1.3), *tzdb*(v.0.3.0), *RcppParallel*(v.5.1.5), *matrixStats*(v.0.62.0), *vroom*(v.1.5.7), *xts*(v.0.12.1), *svglite*(v.2.1.0), *prettyunits*(v.1.1.1), *jpeg*(v.0.1-9), *colorspace*(v.2.0-3), *rvest*(v.1.0.2), *xfun*(v.0.31), *callr*(v.3.7.0), *crayon*(v.1.5.1), *jsonlite*(v.1.8.0), *survival*(v.3.3-1), *zoo*(v.1.8-10), *glue*(v.1.6.2), *gtable*(v.0.3.0), *emmeans*(v.1.7.5), *webshot*(v.0.5.3), *distributional*(v.0.3.0), *pkgbuild*(v.1.3.1), *rstan*(v.2.21.5), *abind*(v.1.4-5), *scales*(v.1.2.0), *mvtnorm*(v.1.1-3), *DBI*(v.1.1.3), *miniUI*(v.0.1.1.1), *viridisLite*(v.0.4.0), *xtable*(v.1.8-4), *htmlTable*(v.2.4.0), *bit*(v.4.0.4), *foreign*(v.0.8-82), *Formula*(v.1.2-4), *stats4*(v.4.2.0), *StanHeaders*(v.2.21.0-7), *DT*(v.0.23), *htmlwidgets*(v.1.5.4), *httr*(v.1.4.3), *threejs*(v.0.3.3), *RColorBrewer*(v.1.1-3), *posterior*(v.1.2.1), *ellipsis*(v.0.3.2), *pkgconfig*(v.2.0.3), *loo*(v.2.5.1), *farver*(v.2.1.0), *nnet*(v.7.3-17), *utf8*(v.1.2.2), *tidyselect*(v.1.1.2), *reshape2*(v.1.4.4), *later*(v.1.3.0), *munsell*(v.0.5.0), *cellranger*(v.1.1.0), *tools*(v.4.2.0), *cli*(v.3.3.0), *generics*(v.0.1.3), *EcdCColors*(v.0.0.0.9000), *ggridges*(v.0.5.3), *evaluate*(v.0.15), *fastmap*(v.1.1.0), *yaml*(v.2.3.5), *bit64*(v.4.0.5), *processx*(v.3.5.3), *nlme*(v.3.1-157), *mime*(v.0.12), *xml2*(v.1.3.3), *compiler*(v.4.2.0), *bayesplot*(v.1.9.0), *shinythemes*(v.1.2.0), *rstudioapi*(v.0.13), *png*(v.0.1-7), *tibble*(v.3.1.8), *stringi*(v.1.7.8), *ps*(v.1.7.0), *Brobdingnag*(v.1.2-7), *forcats*(v.0.5.1), *lattice*(v.0.20-45), *Matrix*(v.1.4-1), *markdown*(v.1.1), *shinyjs*(v.2.1.0), *tensorA*(v.0.36.2), *vctrs*(v.0.4.1), *pillar*(v.1.8.1), *lifecycle*(v.1.0.1), *bridgesampling*(v.1.1-2), *estimability*(v.1.3), *data.table*(v.1.14.2), *httpuv*(v.1.6.5), *R6*(v.2.5.1), *latticeExtra*(v.0.6-29), *promises*(v.1.2.0.1), *gridExtra*(v.2.3), *codetools*(v.0.2-18), *colourpicker*(v.1.1.1), *gtools*(v.3.9.2.1), *assertthat*(v.0.2.1), *rprojroot*(v.2.0.3), *withr*(v.2.5.0), *shinystan*(v.2.6.0), *hms*(v.1.1.1), *grid*(v.4.2.0), *rpart*(v.4.1.16), *coda*(v.0.19-4), *rmarkdown*(v.2.14), *shiny*(v.1.7.1), *base64enc*(v.0.1-3) and *dygraphs*(v.1.1.1.6)

References

- Bürkner, Paul-Christian. 2017. “Brms: An r Package for Bayesian Multilevel Models Using Stan.” *Journal of Statistical Software* 80: 1–28.
- Carpenter, Bob, Andrew Gelman, Matthew D Hoffman, Daniel Lee, Ben Goodrich, Michael Betancourt, Marcus Brubaker, Jiqiang Guo, Peter Li, and Allen Riddell. 2017. “Stan: A Probabilistic Programming Language.” *Journal of Statistical Software* 76 (1).
- Makowski, Dominique, Mattan S Ben-Shachar, and Daniel Lüdtke. 2019. “bayestestR: Describing Effects and Their Uncertainty, Existence and Significance Within the Bayesian Framework.” *Journal of Open Source Software* 4 (40): 1541.
- R Core Team. 2022. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. <https://www.R-project.org/>.